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High-density	 lipoprotein	 cholesterol	 subfractions	 HDL2	 and	 HDL3	 are	
reduced	 in	 women	 with	 rheumatoid	 arthritis	 and	 may	 augment	 the	
cardiovascular	risk	of	women	with	RA:	a	cross-sectional	study.	
	
Atherogenic	 index	 and	 high-density	 lipoprotein	 cholesterol	 as	
cardiovascular	 risk	determinants	 in	 rheumatoid	arthritis:	 the	 impact	of	
therapy	with	biologicals.	
	









































































poor,	women	more	often	 than	men	and	 it	was	 first	described	as	 rheumatoid	arthritis	 (RA)	by	
Archibald	Garrod	 in	1890.[1]	 Its	etiology	was	unclear,	and	many	theories	have	been	proposed	
since	 then.	 Today,	 the	exact	 cause	of	RA	 remains	unknown.	However,	 extensive	 research	has	
generated	much	knowledge	about	its	presentation	and	diagnosis,	the	pathophysiology,	disease	








Despite	 these	 advances,	 cardiovascular	morbidity	 and	mortality	 rates	 in	 patients	with	 RA	 are	
increased	 compared	 to	 the	 general	 population.[7,	 9-11]	 Extensive	 research	 has	 shown	 that	
cardiovascular	 disease	 (CVD)	 accounts	 for	 a	 substantial	 part	 of	 the	 excess	mortality	 found	 in	
















included	 in	 the	 CVD	 risk	 profile	 such	 as	 smoking,	 hypertension,	 diabetes	 mellitus,	 high	 total	
cholesterol	(TC)	levels,	high	levels	of	low-density	lipoprotein	cholesterol	(LDL-c),	or	low	levels	of	
the	 protective	 high-density	 lipoprotein	 cholesterol	 (HDL-c).[26,	 27]	 It	 has	 been	 reported	 that	
these	“traditional”	risk	factors	may	have	a	different	effect	on	CVD	risk	in	RA	patients	compared	
to	 the	general	population.[28-30]	Also,	 the	prevalence	of	certain	risk	 factors	such	as	smoking,	
insulin	resistance,	sedentary	lifestyle	and	hypertension	was	shown	to	be	increased	in	RA.[31-35]	
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At	 the	 same	 time,	 there	 is	 evidence	 that	 suggests	 that	 RA	patients	 are	undertreated	 for	 CVD	
risk.[36,	37].	Interestingly,	it	has	become	evident	that	traditional	risk	factors	do	not	fully	account	
for	the	excess	risk	of	CVD	in	RA.[13,	22,	28,	38]	Therefore,	there	may	be	other	useful	targets	that	




C-reactive	protein	 (CRP),	 an	 inflammatory	marker	used	 to	determine	disease	 activity	 in	RA,	 is	
predictive	for	atherosclerosis.[44,	45]	Indeed,	both	acute	phase	reactants	CRP	and	erythrocyte	
sedimentation	 rate	 (ESR),	 have	 been	 associated	 with	 CVD	 in	 RA	 and	 polyarthritis.[9,	 46-49]	




rupture	and	cause	CVD.[54]	 Inflammation	also	appears	 to	modify	 the	effect	of	 traditional	 risk	
factors,	particularly	lipoproteins.[55-61]	Notably,	the	anti-atherogenic	properties	of	HDL-c	appear	








28-joint	 disease	 activity	 score	 (DAS28).	 The	 DAS28	 is	 a	 combined	 index	 that	 consists	 of	 four	
components;	 number	 of	 swollen	 joints,	 number	 of	 tender	 joints,	 an	 inflammatory	 biomarker	
(either	CRP	or	ESR)	and	the	general	health	score	(Visual	Analogue	scale	[VAS]).	Twenty-eight	joints	





over	 time	 increases	 the	 risk	 of	 CVD.[65,	 66]	 Solomon	et	 al.	 demonstrated	 that	 reduced	 time-	
averaged	disease	activity	was	associated	with	fewer	CV	events	in	a	cohort	of	RA	patients	with	a	














such	 as	CVD.	 Furthermore,	 heterogeneity	of	 patient	 samples,	 fluctuating	disease	 activity	 over	










profile	 in	RA	appears	 to	consist	of	a	complex	 interplay	of	pathophysiological	mechanisms	that	






Figure	 1.1.	 Hypothetical	 distribution	 of	 cardiovascular	 risk	 factors	 in	 patients	 with	 systemic	 lupus	
erythematosus	 or	 rheumatoid	 arthritis	 in	 comparison	 with	 the	 general	 population.	 Risk	 of	
cardiovascular	disease	is	increased	in	these	two	patient	populations,	however	compared	to	the	general	
population	 the	 relative	 contribution	 of	 traditional	 cardiovascular	 risk	 factors	 is	 smaller	 due	 to	









to	 the	 identification	 of	 suitable	 (new)	 risk	 factors	 and	 potential	 therapeutic	 targets.[69]	 Risk	
prediction	in	individuals	can	be	used	for	primary	or	secondary	prevention	and	risk	estimates	can	
also	be	used	to	raise	awareness	of	CVD	within	a	target	population.[69]	Furthermore,	in	clinical	








































term	 storage.	 Therefore,	 in	 Chapter	 2,	 the	 effect	 of	 long-term	 storage	 on	 the	 validity	 of	








lipoproteins	 appear	 to	 be	 modulated	 under	 the	 influence	 of	 inflammation.[57,	 60,	 78-80]	 In	
Chapter	4,	the	effect	of	inflammation	on	the	composition	of	HDL-c	is	determined	in	patients	with	





these	 two	 types	 of	 cholesterol	 seem	 to	 rise	 and	 fall	 in	 the	 same	 direction,	 subsequent	 to	
fluctuations	in	disease	activity	during	the	course	of	RA.[81,	82]	This	phenomenon	has	led	to	the	








long-term	 follow-up	 requires	 further	 clarification.	Therefore,	 the	effect	of	disease	activity	and	
disease	duration	on	the	risk	of	“hard”	CVD	outcomes	was	investigated	in	Chapter	6.	Effective	anti-
rheumatic	 treatment	 seems	 to	 reduce	 CVD	 morbidity	 and	 mortality.[67,	 83-85]	 Treatment	
strategies	 aimed	 at	 significant	 reduction	 or	 even	 complete	 (clinical)	 eradication	 of	 the	
inflammatory	auto-immune	response	(i.e.	remission)	in	RA	may	reduce	CVD	risk	even	further.	In	
Chapter	 7,	 the	 effect	 of	 low	disease	 activity	 and	 remission	 over	 time	on	 the	 risk	 of	 CVD	was	
investigated.	Finally,	this	thesis	focuses	on	the	development	of	a	CVD	risk	model	specifically	suited	
for	use	in	RA	patients.	In	Chapter	8,	the	SCORE	risk	model	was	recalibrated	and	adapted	for	use	
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Cardiovascular	 risk	 is	 increased	 in	 patients	 with	 rheumatoid	 arthritis	 (RA).[1]	 Cardiovascular	
disease	 (CVD)	accounts	 for	50%	of	all	excess	mortality	 in	RA	patients.[1]	RA	 itself	as	a	chronic	
inflammatory	condition	may	increase	CVD	risk.	Also,	studies	have	shown	that	inflammation	may	
modulate	traditional	CVD	risk	factors.[2,	3]	Atherosclerotic	plaques	in	the	carotid	artery	appear	
more	 severe	 and	 prevalent	 in	 RA	 patients	 compared	 to	 the	 general	 population.[4–7]	 In	
comparison	to	healthy	controls	and	RA	patients	in	remission,	RA	patients	with	active	disease	seem	
to	have	less	stable	plaques	that	are	more	vulnerable	to	rupture,	which	increases	the	probability	
of	 a	 cardiovascular	 event.	 Considering	 the	 increased	 risk,	 prevention	 of	 CVD	 is	 important.	










risk	 factors,	might	 also	 be	 taken	 into	 consideration.[13–17]	 There	 is	 an	 unmet	 need	 for	 a	 RA	
specific	CVD	risk	calculator.	In	order	to	evaluate	current	risk	models	and	develop	and	validate	an	
RA	specific	CVD	risk	model,	it	would	be	advantageous	to	use	data	from	existing	cohorts	with	long	
follow-up.	 In	existing	cohorts	of	RA	patients,	 lipid	 levels	are	often	not	determined	at	baseline.	























Serum	samples	 taken	at	baseline	and	at	1,	2,	3,	5,	7,	and	10	years	of	 follow-up	 from	patients	
included	in	the	RA	inception	cohort	of	the	Radboud	University	Nijmegen	Medical	Centre,	from	
1985	up	 to	2009	 (!	=	640),	were	used	 for	measurements	of	 lipoproteins.	To	 test	 for	a	period	
effect,	 patients	were	 stratified	 in	 five	 subcohorts	 according	 to	 year	 of	 inclusion	 in	 the	 cohort	
during	1985–1989,	1990–1994,	1995–1999,	2000–2004,	and	2005–2009	 (Figure	1).	The	 study	
















From	 this	 cohort,	 we	 selected	 at	 random	 150	 RA	 patients	 from	 the	 inception	 cohort	 using	
computer	generated	random	numbers,	to	obtain	30	samples	per	subcohort.	
Serum	Samples	
During	 follow-up,	 nonfasting	 blood	 samples	 were	 drawn	 annually	 by	 a	 trained	 nurse.	
Approximately	400	mL	of	serum	was	stored	from	each	sample	and	divided	into	four	separate	vials.	




baseline	 and	 during	 follow-up	 (at	 1,	 2,	 3,	 5,	 7,	 and	 10	 years)	were	 extracted	 from	 storage	 in	
January	 2012.	 Immediately	 following	 this	 procedure,	 samples	 were	 prepared	 for	 cholesterol	
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were	 considered	 as	 potential	 confounders:	 age,	 gender,	 statin	 use	 at	 baseline,	 BMI,	 smoking,	
blood	 pressure,	 28-joint	 disease	 activity	 score	 (DAS28),	 rheumatoid	 factor	 positivity,	 and	
glucocorticosteroid	use.	Variables	were	considered	confounders	if	their	addition	to	the	model	led	
to	 a	 >10%	 change	 in	 one	 of	 the	 subcohort	 follow-up	 time	 effects.	 For	 the	 development	 of	 a	
correction	factor	for	the	storage	decay	effect,	linear	mixed	models	were	used,	with	cholesterol	






cholesterol	 level	 ("observed),	 it	 gives	 an	 estimate	 of	 the	 “original”	 cholesterol	 value	 ($).	















(Table	1),	with	storage	 times	 ranging	 from	1	 to	26	years.	Samples	 from	the	oldest	 subcohorts	
comprised	the	longest	storage	times.	Serum	samples	from	seven	time	points	(0,	1,	2,	3,	5,	7,	and	















Age	(years),	mean±SD	 51±14.4	 50±13.5	 52±14.5	 58±12.1	 59±12.6	
Female,	N(%)	 16	(53.3)	 19	(61.3)	 17	(56.7)	 25	(83.3)	 21	(67.7)	
RF	positive,	N(%)	 26	(86.7)	 23	(74.2)	 25	(83.3)	 23	(76.7)	 25	(80.6)	
DAS28,	mean±SD	 5.6±1.2	 5.3±1.4	 4.8±1.6	 4.9±1.0	 5.0±1.2	
BMI,	mean±SD	 26±3.8	 27.1±4.6	 25.6±3.3	 26.2±3.0	 26.6±6.8	
Smokers,	N(%)	 14	(46.7)	 6	(19.4)	 10	(33.3)	 9	(30.0)	 9	(29.0)	
Statin	use,	N(%)	 0	(0.0)	 0	(0.0)	 2	(6.7)	 2	(6.7)	 9	(29.0)	

























Treatment	during	follow-up	 	 	 	 	 	








course	 of	 lipid	 levels	 during	 storage	 time.	 The	 unadjusted	 results	 (not	 shown)	 revealed	 a	
significant	interaction	effect	between	subcohort	and	follow-up	time	for	TC	and	LDL-c	(p=0.02	and	
p=0.01,	resp.).	Overall,	the	course	of	the	various	lipoprotein	levels	over	time	was	not	significantly	























will	 therefore	 become	 higher	 as	 a	 direct	 result	 of	 increasing	 storage	 time	 and	 the	
disproportionate	decay	effect	on	TC	and	HDL-c.	This	lipid	decay	was	estimated	to	be	linear.	A	lipid	
decay	correction	factor	was	calculated	to	be	[y	=	observed	+	(Chol		t	)];	0.03	mmol/L	for	TC	and	











	 Estimate	 SE	 P-value	 95%	CI	
	 	 	 	 Lower	 Upper	
Constant	 3.41	 0.39	 <.001	 2.65	 4.17	
Storage	time	 −.03	 0.01	 <.001	 −.05	 −.02	
Time	within	patients	(follow-up)	 0.01	 0.00	 <.001	 0.00	 0.02	
Time2	(follow-up)	 −.00	 0.00	 <.001	 −.00	 −.00	
Gender	 0.02	 0.10	 0.81	 −.17	 −.21	
Age	 0.02	 0.04	 <.001	 0.09	 0.02	
Statin	use	at	baseline	 0.89	 0.19	 <.001	 0.52	 1.26	
BMI	 0.01	 0.01	 0.34	 −.01	 0.03	








	 Estimate	 SE	 P-value	 95%	CI	
	 	 	 	 Lower	 Upper	
Constant	 1.25	 0.06	 <.001	 1.14	 1.36	
Storage	time	 −.02	 0.00	 <.001	 −.03	 −.02	
Time	within	patients	(follow-up)	 0.00	 0.00	 <.001	 0.00	 0.00	
Time2	(follow-up)	 −.00	 0.00	 <.001	 −.00	 −.00	
Gender	 −.07	 0.02	 0.001	 -.1.2	 0.03	





lipoprotein	 levels,	 increases	 as	 storage	 time	 increases.	 To	 better	 approximate	 the	 lipoprotein	
levels	 at	 the	 time	 the	 serum	 sample	 was	 taken,	 and	 the	 lipid	 decay	 correction	 factor	 was	
estimated.	Correction	 for	 the	 storage	decay	effect	will	 yield	 a	 lower	 (improved)	 TC:HDL	 ratio,	
which	reduces	the	calculated	CVD	risk.	After	applying	the	storage	correction	factor,	the	TC:HDL-c	




















Low	(<10%)		 499	(48%)	 552	(53%)	 +53	 (11%)	
Intermediate	(10-20%)	 178	(17%)	 164	(16%)	 −14	(8%)	
High	(>20%)	 373	(35%)	 334	(31%)	 -39	(11%)	




















































during	 that	 same	 timeframe.	 Overall,	 these	 subcohorts	 did	 not	 seem	 to	 differ	 significantly,	


























valuable	 source	of	data.	These	data	can	be	of	particular	 importance	 for	 studies	 in	RA	cohorts	
involving	 long-term	outcomes	such	as	cardiovascular	disease.	 In	addition,	 it	may	be	 financially	
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models	 for	 the	 10-year	 risk	 of	 fatal	 and	 non-fatal	 cardiovascular	 disease	 (CVD)	 in	 European	
patients	with	rheumatoid	arthritis	(RA).		
Methods		
Data	 from	 the	Nijmegen	early	 rheumatoid	 arthritis	 inception	 cohort	was	used.	Discriminatory	
ability	 for	 CVD	 risk	 prediction	 was	 estimated	 by	 the	 area	 under	 the	 receiver	 operating	






Coronary	 Risk	 Evaluation	 (SCORE),	 Framingham	 risk	 score	 (FRS)	 and	Reynolds	 risk	 score	 (RRS)	
primarily	 underestimated	 CVD	 risk	 at	 low	 and	 middle	 observed	 risk	 levels,	 and	 mostly	
overestimated	 CVD	 risk	 at	 higher	 observed	 risk	 levels.	 The	 QRisk	 II	 primarily	 overestimated	













the	 risk	 of	 CVD	 is	 increased	 and	 screening	 of	 CVD	 risk	 factors	 and	 identiﬁcation	 of	 high-risk	
patients	is	warranted.[6]	Risk	algorithms	developed	for	the	general	population	do	not	necessarily	









extra	 risk.[11]	 In	 the	 general	 population,	 inﬂammation	 has	 been	 shown	 to	 be	 an	 important	
independent	 risk	 factor	 for	 CVD.[12]	 The	 RRS	 incorporates	 the	 inﬂammatory	 marker	 high-







of	 extra-articular	 manifestations.	 Recently,	 an	 updated	 version	 of	 the	 QRisk	 algorithm	 was	
developed	by	Hippisley-Cox	et	al.[3]	This	QRisk	II	algorithm	includes	RA	as	an	independent	risk	
factor.	However,	it	is	not	known	whether	the	M-SCORE,	RRS	and	QRisk	II	risk	algorithms	predict	
future	 CVD	 in	 patients	 with	 RA	 more	 accurately	 compared	 with	 the	 SCORE	 or	 the	 FRS.	 The	
predictive	performance—that	is,	the	accuracy	of	predictions	of	future	CVD	event(s)—of	these	risk	
algorithms	has	not	been	evaluated	and	compared	in	European	patients	with	RA.	Therefore,	the	
objective	 of	 this	 study	 is	 to	 assess	 the	 performance	 of	 four	 established	 CVD	 risk	 algorithms	





















(male/female),	 rheumatoid	 factor	 positivity,	 anticyclic	 citrullinated	 peptide	 positivity,	 28-joint	
disease	 activity	 score	 and	CRP	 (mg/L).	Data	on	CVD	 risk	 factors	 at	 baseline	were	 collected	by	
medical	chart	and	electronic	patient	ﬁle	review,	including	smoking	status	(Y/N),	blood	pressure	
(mm	Hg),	use	of	statins	(Y/N)	and	antihypertensive	medication	(Y/N),	height	(m)	and	weight	(kg),	
diabetes	mellitus	 (Y/N),	 hypertension	 (Y/N)	 and	 family	 history	 of	 CVD	 (Y/N).	 Lipid	 levels	were	
measured	using	serum	from	frozen	samples	collected	at	baseline.	Non-fasting	total	cholesterol	




diagnosis	 and	 extensive	 review	 of	 medical	 charts	 and	 electronic	 patient	 ﬁles.	 Included	
cardiovascular	 events	 were:	 acute/unstable	 coronary	 syndrome	 (myocardial	 infarction	 and	




















discriminatory	 ability	 of	 the	 four	 algorithms	was	 estimated	using	 the	 area	 under	 the	 receiver	
operating	characteristic	(ROC)	curve,	which	is	similar	to	the	concordance-statistic	(c-statistic).[18]	





the	 calibration	 plots,	 a	 line	was	 ﬁtted	 between	 the	 observed	 and	 predicted	 probabilities	 of	 a	
cardiovascular	event	per	decile	of	predicted	risk	using	quadratic	spline.	Sensitivity	and	speciﬁcity	
were	calculated	for	the	cut-off	values	of	10%	and	20%	that	mark	the	difference	between	low-risk	
and	 intermediate-to-high	 risk	 and	 between	 low-intermediate	 risk	 and	 high-risk	 patients,	














was	 adjusted	 to	 ﬁt	 each	 CVD	 risk	 algorithm,[2–5	 9]	 leaving	 104,	 149,	 87	 and	 126	 ﬁrst	
cardiovascular	events	for	analysis	of	SCORE,	FRS,	RRS	and	QRisk	II,	respectively.	As	the	RRS	is	not	
applicable	to	patients	with	diabetes,	these	patients	(n=44)	were	excluded,	leaving	a	total	of	1006	






(95%CI	 0.73	 to	 0.82)	 and	 0.79	 (95%CI	 0.75	 to	 0.83)	 for	 the	 SCORE,	 FRS,	 RRS	 and	 QRisk	 II,	
respectively.	The	corresponding	ROC	curves	are	presented	in	ﬁgure	1.	
Calibration	













Age	(years),	mean±SD	 54±13.8	 53±13.9	 61±10.2	 <.001	
Female,	n(%)	 695	(66)	 616	(68)	 79	(53)	 <.001	
DAS28	at	baseline,	mean±SD	 4.9±1.3	 4.8±1.3	 5.4±1.3	 0.001	
Swollen	joint	count,	median	(	p25–p75)	 7	(5–12)	 7	(5–11)	 9	(6–14)	 0.002	
Tender	joint	count,	median	 (	p25–p75)	 5	(3–9)	 5	(3–9)	 7	(4–12)	 <.001	
ESR	 (mm/hour),	median	 (	p25–p75)	 25	(16–45)	 23	(16–44)	 34	(20–50)	 0.001	
CRP	(mg/L),	median	(	p25–p75)	 16	(3–42)	 15	(3–41)	 22	(5–47)	 0.078	
VAS	 (mm),	median	 (	p25–p75)	 41	(30–57)	 40	(29–55)	 50	(32–64)	 0.002	
Rheumatoid	 factor	 positivity,	n(%)	 777	(74)	 658	(73)	 118	(79)	 0.110	
Anti-CCP	positivity,	 n(%)	 681	(65)	 572	(64)	 91	(61)	 0.510	
Smoking	at	baseline,	n(%)	 332	(32)	 265	(29)	 60	(41)	 0.003	
BMI	 (weight(kg)/Height(m)
2
),	mean±S	 26±4.3	 26±4.4	 26±4.1	 0.038	
Systolic	blood	 pressure	 (mmHg),	mean±SD	 146±24	 145±24	 155±25	 <.001	
Diastolic	blood	pressure	 (mmHg),	mean±SD	 84±12	 83±12	 86±10	 0.004	
Total	cholesterol	 (mmol/L),	mean±SD	 5.1±1.2	 5.2±1.2	 5.3±1.4	 0.127	
HDL-cholesterol	 (mmol/L),	mean±SD	 1.3±0.3	 1.3±0.3	 1.2±0.3	 0.124	
TC:HDLc	 ratio,	mean±SD	 4.2±0.9	 4.1±1.1	 4.4±1.0	 0.010	
Diabetes	at	baseline,	n(%)	 44	(4)	 30	(3)	 14	(10)	 <.001	











Treatment	with	statins	at	baseline,	n(%)	 38	(4)	 28	(3)	 10	(7)	 0.061	
Family	history	 of	CVD,	n(%)	 326	(25)	 281	(31)	 53	(36)	 0.386	
SCORE	 (%),	median	 (	p25–p75)	 9	(3–28)	 7	(2–23)	 28	(11–48)	 <.001	
FRS	(%),	 median	(	p25–p75)	 13	(5–23)	 11	(5–20)	 23	(15–33)	 <.001	
RRS*	(%),	median	(	p25–p75)	 6	(2–17)	 5	(1–14)	 17	(7–30)	 <.001	












3A).	 The	 H-L	 test	 yielded	 a	 p-value	 of	 <0.001,	 indicating	 poor	 model	 ﬁt.	 The	 number	 of	













Figure	1.	Receiver	 operating	characteristic	(ROC)-curves	for	the	different	 risk	algorithms.	 Area	under	the	curve	
(AUC)-values	(95%	CI)	are	0.78	(0.74	to	0.82),	0.80	(0.77	to	0.84),	0.78	(0.73	to	0.82)	and	0.79	(0.75	to	0.83)	


















































SCORE	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 104	 410	 79	 331	 25	 615	 1050	 76	 65	 19	 96	
	>20%	 104	 247	 63	 184	 41	 762	 1050	 61	 80	 26	 95	
FRS	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 149	 487	 130	 357	 19	 544	 1050	 87	 60	 27	 97	
	>20%	 149	 144	 88	 161	 61	 740	 1050	 59	 82	 35	 92	
RRS	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 87	 284	 59	 255	 28	 694	 1006	 68	 76	 21	 96	
	>20%	 87	 144	 33	 111	 54	 808	 1006	 40	 88	 23	 94	
QRisk	II	 	 	 	 	 	 	 	 	 	 	 	
	>10%	 126	 516	 106	 410	 20	 514	 1050	 84	 55	 21	 96	


















mainly	 overestimating	 (QRisk	 II)	 and	 underestimating	 (SCORE,	 FRS,	 RRS)	 the	 risk	 of	 future	 CV	
events	in	European	patients	with	RA.	This	underestimation	was	most	pronounced	in	the	lower	













algorithms	 in	 patients	 with	 RA	 with	 the	 predictive	 performance	 reported	 in	 the	 general	
population,	discriminative	ability	appears	comparable.[3,	5,	9,	19]	However,	in	the	RA	population	




with	a	 c-statistic	 score	of	0.75	 in	men	and	0.71	 in	women.[9]	 In	an	American	cohort,	 the	FRS	


























CRP.	 Regular	 CRP	 was	 used	 to	 calculate	 CVD	 risk	 with	 the	 RRS	 algorithm	 whereas	 hs-CRP	 is	
indicated,[4,	 5]	 which	 could	 have	 affected	 the	 predicted	 probabilities.	 However,	 sensitivity	
analysis	for	CRP	values	<5	mg/L	showed	no	different	outcomes	when	setting	these	values	at	either	
0	mg/L	or	5	mg/L	 (not	 shown).	 Future	 research	 is	necessary	 to	determine	whether	other	RA-
speciﬁc	baseline	 components	 that	better	 reﬂect	 future	disease	 activity	may	 improve	CVD	 risk	
prediction.	However,	simply	adding	disease	speciﬁc	parameters	may	not	be	sufﬁcient	to	boost	





















In	 conclusion,	 the	 SCORE,	 RRS,	 FRS	 and	 QRisk	 II	 algorithms	 tend	 to	mainly	 underestimate	 or	
overestimate	 CVD	 risk	 in	 a	 large	 portion	 of	 the	 RA	 population	 and	 provide	 less	 accurate	
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and	may	 impair	 its	anti-atherogenic	effect.	Changed	HDL-c	composition	through	the	 impact	of	
inflammation	 on	 HDL-c	 subfractions	may	 contribute	 to	 the	 excess	 risk	 of	 CVD	 in	 rheumatoid	












controls	 (P	 =	 0.04).	 Reduced	 HDL2-c	 and	 HDL3-c	 levels	 were	 primarily	 present	 in	 female	 RA	
patients	 and	 not	 in	male	 RA	 patients.	 A	modest	 effect	 of	 the	 28-joint	 disease	 activity	 score	 (	




















suggested	 that	 inflammation	plays	an	 important	 role	 in	mediating	 cardiovascular	 risk	 in	 these	
patients.[5,6]	In	RA,	it	has	been	shown	that	inflammation	affects	the	lipid	profile	and	accelerates	




lipoprotein	cholesterol	 (HDL-c)	or	a	pro-atherogenic	 lipid	profile,	are	 important	risk	factors	for	
CVD.[10]	In	the	general	population,	HDL-c	is	regarded	as	the	main	anti-atherogenic	lipoprotein	
and	increased	levels	of	HDL-c	have	been	associated	with	a	protective	effect	against	cardiovascular	
mortality	and	morbidity.[11,12]	The	beneficial	effect	of	HDL-c	appears	 to	be	 the	strongest	 for	
women.[12]	This	advantageous	effect	of	HDL-c	is	supposed	to	be	accomplished	primarily	through	
the	 reverse	 cholesterol	 transport	 (RCT)	 and	 the	 neutralization	 of	 oxidized	 lipids.[13]	 In	 RA	
patients,	 however,	 the	 effect	 of	 changes	 in	 lipid	 concentrations	 on	 CVD	 risk	 is	 less	 straight	
forward.[8]	Lipoprotein	and	apolipoprotein	levels	are	known	to	fluctuate	during	the	course	of	RA,	





levels	 of	 HDL-c,[14,18,19]	 inflammation	 may	 reduce	 the	 anti-oxidative	 capacity,	 impair	 RCT	
capacity	of	HDL-c	in	RA	patients,	and	even	lead	to	HDL-c	becoming	pro-atherogenic.[20-23]	The	
functionality	of	HDL-c	is	partially	dependent	on	HDL-c	composition.	Based	on	its	density	HDL-c	
can	 be	 divided	 into	 two	main	 subfractions:	 HDL2-cholesterol	 (HDL2-c)	 and	 the	 smaller	 HDL3-
cholesterol	 (HDL3-c).	HDL2-c	has	been	suggested	 to	be	 the	more	variable	component	of	 total	
HDL,	while	primarily	higher	levels	of	the	HDL2-c	subfraction	contribute	to	the	anti-atherogenic	













This	 is	 a	 cross-sectional	 study	 comparing	 a	 group	 of	 45	 consecutive	 patients	with	 RA,	with	 a	
control	group	of	45	consecutive	healthy	individuals.	RA	patients	were	included	in	the	study	if	they	












tubes	 (Beckton	 Dickinson,	 Rutherford,	 New	 Jersey,	 USA)	 containing	 K3-	




each	 run,	 samples	 from	both	 patients	 and	 controls	were	 analyzed	 to	 prevent	 any	within	 and	
between	 run	 variability	 to	 affect	 group	 differences	 in	 HDL-c	 subfraction	 levels.	 Low-density	
lipoprotein	(LDL)	cholesterol	levels	were	calculated	according	to	the	Friedewald	formula,	which	
provides	reliable	values	up	to	a	TG	concentration	of	4.0	mmol/L.	ApoB	and	ApoA-I	levels	(mg/L)	



















with	 HDL2-c	 or	 HDL3-c	 concentrations	 as	 the	 dependent	 variable,	 disease	 activity	 as	 the	
independent	variable,	and	age,	gender,	smoking,	BMI,	rheumatoid	factor	positivity	and	disease	
duration	as	potential	confounders.	Additional	analyses	were	performed	to	investigate	the	effect	











were	 included,	 13	men	 and	 32	 women	 with	 a	 mean±SD	 age	 of	 54±6	 years	 and	 55±8	 years,	
respectively.	The	participants	 in	 the	control	 group	were	on	average	5	years	 younger	 than	 the	
patients	in	the	RA	group	(Table	1).	Patient	characteristics	are	presented	in	Table	1.	
Table	1.	Patient	characteristics		
	 RA	patients	(n	=	45)	 Healthy	 controls	(n	=	45)	




ESR,	median	 (P25	 to	P75)	 14	(5	to	28.5)	 N/A	



















Apo	A-1	 levels	were	 lower	 (Table	2).	Notably,	both	HDL-c	 sub	 fractions	HDL2-c	 (P	=	0.01)	and	
HDL3-c	(P	=	0.005)	were	significantly	reduced	in	RA	patients	(Figure	1).	Results	regarding	HDL2-c	
concentrations	demonstrated	a	larger	difference	between	RA	patients	and	controls,	compared	to	




	 RA	Patients	(n=45)	 Healthy	controls	(n=45)	 P-value	
Lipids	(mmol/L),	mean±SD		 	 	 	
TC,	mean±SD	 5.7±1.1	 5.7±0.8	 0.72	
TG,	mean±SD	 2.1±1.2	 1.6±0.8	 0.04	
HDL-c,	mean±SD	 1.3±0.3	 1.6±0.3	 <.001	
			HDL2-c	 0.5±0.3	 0.7±0.4	 0.01	
			HDL3-c	 0.8±0.2	 0.9±0.2	 0.005	
			HDL2-c:HDL3-c	 0.5±0.3	 0.7±0.4	 0.04	
LDL-c,	mean±SD	 3.5±0.9	 3.3±0.7	 0.41	
Apolipoproteins	(mg/L)		 	 	 	
Apo	A-1,	mean±SD	 1517.2±242.2	 1710±217.2	 <.001	
Apo	B,	mean±SD	 987.5±220.3	 862.2±188.8	 0.005	
i. Apo,	apolipoprotein;	HDL,	high	 density	 lipoprotein;	 LDL,	 low	density	lipoprotein;	 n,	




























and	women	 (P	 =	 0.13	 and	 P	 =	 0.20,	 respectively).	 Therefore,	 the	 difference	 between	 RA	 and	
healthy	controls	was	analyzed	for	men	and	women	separately.	In	men,	the	differences	between	
RA	and	healthy	controls	in	HDL2-c	(0.011	mmol/L,	95%	confidence	interval	(CI)	-0.17	to	0.15)	and	
HDL3-c	 (0.007	 mmol/L,	 95%CI	 -0.16	 to	 0.18)	 were	 not	 significant	 (P	 =	 0.89	 and	 P	 =	 0.93,	
respectively)	(figure	2).	For	women,	these	differences	between	RA	patients	and	controls	in	HDL2-
c	 (0.27	 mmol/L,	 95%CI	 0.10	 to	 0.45)	 and	 HDL3-c	 (0.16	 mmol/L,	 95%CI	 0.08	 to	 0.23)	 were	
significant	 (P	 =	 0.003	 and	 P	 <	 0.001,	 respectively).	 After	 repeating	 the	 analyses	 using	 linear	
regression	with	an	interaction	term	for	group	and	gender	(see	methods),	it	appeared	that	there	
were	interactions	regarding	gender	and	presence	of	RA	for	HDL2-c	(P	=	0.055),	as	well	as	for	HDL3-
c	 (P	 =	 0.063).	 In	women,	 the	HDL2-c:HDL3-c	 ratio	was	 significantly	 different	 between	RA	 and	
controls,	 with	 a	mean	 difference	 of	 0.2	 (95%	 CI	 0.04	 to	 0.40,	 P=	 0.02)	 compared	 to	 a	mean	
difference	of	0.01	(95%	CI	-0.2	to	0.1,	P	=	0.9)	in	men.	These	findings	are	mirrored	in	TG,	Apo	A-I	











regression	 analysis,	 with	 gender,	 age,	 disease	 duration	 and	 use	 of	 glucocorticosteroids	 as	
covariates,	 while	 smoking,	 BMI	 and	 rheumatoid	 factor	 were	 not	 acting	 as	 confounders.	 A	
statistically	 small	 effect	 of	 DAS28	 on	 HDL2-c	 was	 found	 (Figure	 3).	 HDL2-c	 concentration	
HDL2-chol and HDL3-chol concentrations. The mean ±
SD HDL2-chol and HDL3-chol levels in users and non-
users of methotrexate, biologicals and glucocorticoster-
oids are presented in Table 3. The subanalysis of HDL2-
chol and HDL3-chol levels in non-users and users of
glucocorticosteroids (at the time of the study) showed
moderately lower mean concentrations of HDL2-chol
and moderately higher HDL3-chol levels in users (Table
3), without reaching statistical significance. Glucocorti-
costeroid use and mean prescribed dosage was similar
in men and women (not shown). Disease duration was
considered a confounder as well. In patients with a
longer disease duration (≥10 years) versus patients with
a shorter disease duration (<10 years), higher levels of
both HDL2-chol (mean ± SD 0.6 ± 0.4 versus 0.3 ± 0.1)
and HDL3-chol (mean ± SD 0.9 ± 0.1 versus 0.7 ± 0.2)
concentrations were found. Interestingly, in this study,
women had a longer mean ± SD disease duration (18 ±
11 years versus 8 ± 7 years in men) and a higher mean
± SD DAS28 score (3.4 ± 1.8 versus 2.4 ± 1.2).
Discussion
This study is the first to investigate the distribution of
HDL subfractions in RA patients. According to our
results, both HDL subfractions but particularly HDL2-
chol concentrations were decreased in RA, leading to a
decreased HDL2:HDL3 ratio in these patients. Intrigu-
ingly, the differences in HDL subfractions between RA
and controls were most evident in women, whereas simi-
lar levels of HDL2-chol and HDL3-chol have been
observed in men. Disease activity was not strongly related
to the level of HDL2-chol or HDL3-chol. Finally, our
results suggest that the low HDL2-chol concentration
might contribute to the previously reported increased
cardiovascular risk in RA women.
Results from previous studies investigating HDL and its
anti-atherogenic properties in inflammatory conditions
such as RA, indicate that HDL function deteriorates and
may even become pro-atherogenic in these patients
[20-23]. An inverse relation between HDL3-chol and risk
of CVD has been previously reported [28,29]. When
comparing HDL subfraction levels in cases with CVD
and controls the largest differences were found in HDL2-
chol concentrations, and often stronger inverse associa-
tions between HDL2-chol and CVD were reported
[24-26,30]. This is in accordance with our results; the lar-
gest difference between RA patients and controls was
found in HDL2-chol concentrations, and, consequently,
the HDL2:HDL3 ratio was lower in this group. This fact
might translate into an impaired RCT, one of the crucial
anti-atherogenic mechanisms involving HDL. The RCT
relies on the quantity of both HDL2-chol and HDL3-
chol. Several enzymes, including cholesterylester transfer
protein (CETP) may affect HDL2-chol and HDL3-chol
Figure 2 HDL2-chol and HDL3-chol subfractions in male and female RA patients (RA) and healthy controls (HC). The observed
differences in mean HDL3-chol and particularly HDL2-chol levels (mmol/L) between RA patients and controls were primarily present in women,
not men. In women, the differences between RA patients and healthy controls in HDL2-chol and HDL3-chol were larger; 0.27 mmol/L (95%CI
0.09 to 0.45) for HDL2-chol, and 0.16 mmol/L, (95% CI 0.08 to 0.23) for HDL3-chol. CI, confidence interval; HDL, high density lipoprotein; RA,
rheumatoid arthritis.
Figure 3 HDL2-chol and HDL3-chol concentrations in a group
of RA patients with low, moderate and high disease activity
levels. HDL2-chol and HDL3-chol concentrations were similar across
all categories of the DAS28 (low <3.2; n = 31, medium 3.2 to 5.1; n
= 6, and high >5.1; n = 8). The results of the regression analysis
showed a small effect of DAS28 on HDL2-chol; a decrease in HDL2-
chol of 0.06 mmol/L with every point increase in DAS28 (P = 0.05).
Disease activity did not significantly relate to HDL3-chol, which
decreased by 0.02 mmol/L with every point increase in DAS28 (P =
0.19). DAS28, disease activity score (28 joints); HDL, high density
lipoprotein; n, number; RA, rheumatoid arthritis.
Arts et al. Arthritis Research & Therapy 2012, 14:R116
http://arthritis-research.com/content/14/3/R116




decreased	by	0.06	mmol/L	with	every	point	 increase	 in	DAS28	 (P	=	0.05),	while	correcting	 for	
gender,	age,	disease	duration	and	use	of	glucocorticosteroids.	Disease	activity	did	not	significantly	
relate	to	HDL3-c,	which	decreased	by	0.02	mmol/L	with	every	point	increase	in	DAS28	(P	=	0.19),	
while	 correcting	 for	 gender,	 age,	 disease	 duration	 and	 use	 of	 glucocorticosteroids.	 The	
inflammatory	marker	ESR	was	significantly	associated	with	HDL2-c	(P	=	0.046)	and	HDL3-c	(P	=	
0.006),	while	correcting	for	gender,	age,	disease	duration	and	use	of	glucocorticosteroids.	(CRP	














higher	 HDL3-c	 levels	 in	 users	 (Table	 3),	 without	 reaching	 statistical	 significance.	
Glucocorticosteroid	use	and	mean	prescribed	dosage	was	similar	in	men	and	women	(not	shown).	
In	 patients	 with	 a	 longer	 disease	 duration	 (≥10	 years)	 versus	 patients	 with	 a	 shorter	 disease	
duration	(<10	years),	higher	levels	of	both	HDL2-c	(mean±SD	0.6±0.4	versus	0.3±0.1)	and	HDL3-c	
(mean±SD	0.9±0.1	versus	0.7±0.2)	concentrations	were	found.	Interestingly,	in	this	study,	women	
had	 a	 longer	mean±SD	disease	 duration	 (18±11	 years	 versus	 8±7	 years	 in	men)	 and	 a	 higher	
mean±SD	DAS28	score	(3.4±1.8	versus	2.4±1.2).	
HDL2-chol and HDL3-chol concentrations. The mean ±
SD HDL2-chol and HDL3-chol levels in users and non-
users of methotrexate, biologicals and glucocorticoster-
oids are presented in Table 3. The subanalysis of HDL2-
chol and HDL3-chol levels in non-users and users of
glucocorticosteroids (at the time of the study) showed
moderately lower mean concentrations of HDL2-chol
and moderately higher HDL3-chol levels in users (Table
3), without reaching statistical significance. Glucocorti-
costeroid use and mean prescribed dosage was similar
in men and women (not shown). Disease duration was
considered a co founder as well. In patients with a
longer disease duration (≥10 years) versus patients with
a shorter disease dur tion (<10 years), higher levels of
both HDL2-chol (mean ± SD 0.6 ± 0.4 versus 0.3 ± 0.1)
and HDL3-ch l (me ± SD 0.9 ± 0.1 versus 0.7 ± 0.2)
concentrations were found. Interestingly, in this study,
women had a longer mean ± SD disease duration (18 ±
11 years versus 8 ± 7 years in men) and a higher mean
± SD DAS28 score (3.4 ± 1.8 versus 2.4 ± 1.2).
Discussion
This study is the first to investigate the distribution of
HDL subfractions in RA patients. According to our
results, both HDL subfractions but particularly HDL2-
chol concentrations were decreased in RA, leading to a
decreased HDL2:HDL3 ratio in these patients. Intrigu-
ingly, the differences in HDL subfractions between RA
and controls were most evident in women, whereas simi-
lar levels of HDL2-chol and HDL3-chol have been
observed in men. Disease activity was not strongly related
to the level of HDL2-chol or HDL3-chol. Finally, our
results suggest that the low HDL2-chol concentration
might contribute to the previously reported increased
cardiovascular risk in RA women.
Results from previous studies investigating HDL and its
anti-atherogenic properties in inflammatory conditions
such as RA, indicate that HDL function deteriorates and
may even become pro-atherogenic in these patients
[20-23]. An inverse relation between HDL3-chol and risk
of CVD has been previously reported [28,29]. When
comparing HDL subfraction levels in cases with CVD
and controls the largest differences were found in HDL2-
chol concentrations, and often stronger inverse associa-
tions between HDL2-chol and CVD were reported
[24-26,30]. This is in accordance with our results; the lar-
gest difference between RA patients and controls was
found in HDL2-chol concentrations, and, consequently,
the HDL2:HDL3 ratio was lower in this group. This fact
might translate into an impaired RCT, one of the crucial
anti-atherogenic mechanisms involving HDL. The RCT
relies on the quantity of both HDL2-chol and HDL3-
chol. Several enzymes, including cholesterylester transfer
protein (CETP) may affect HDL2-chol and HDL3-chol
Figure 2 HDL2-chol and HDL3-chol subfractions in male and female RA patients (RA) and healthy controls (HC). The observed
differences in mean HDL3-chol and particularly HDL2-chol levels (mmol/L) between RA patients and controls were primarily present in women,
not men. In women, the differences between RA patients and healthy controls in HDL2-chol and HDL3-chol were larger; 0.27 mmol/L (95%CI
0.09 to 0.45) for HDL2-chol, and 0.16 mmol/L, (95% CI 0.08 to 0.23) for HDL3-chol. CI, confidence interval; HDL, high density lipoprotein; RA,
rheumatoid arthritis.
Figure 3 HDL2-ch l and HDL3-chol conc trati ns in a group
of RA patients with low, moderate and high disease activity
levels. HDL2-chol and HDL3-chol concentrations were similar across
all categories of the DAS28 (low <3.2; n = 31, medium 3.2 to 5.1; n
= 6, and high >5.1; n = 8). The results of the regression analysis
showed a small ffect of DAS28 on HDL2-chol; a decr as i HDL2-
chol of 0.06 mmol/L with every point increase in DAS28 (P = 0.05).
Disease activity did not significantly relate to HDL3-chol, which
decreased by 0.02 mmol/L with every point increase in DAS28 (P =
0.19). DAS28, disease activity score (28 joints); HDL, high density
lip protein; n, number; RA, r eumatoid arthritis.
Arts et al. Arthritis Research & Therapy 2012, 14:R116
http://arthritis-research.com/content/14/3/R116













of	 HDL2-c	 or	 HDL3-c.	 Finally,	 our	 results	 suggest	 that	 the	 low	 HDL2-c	 concentration	 might	
contribute	to	the	previously	reported	increased	cardiovascular	risk	 in	RA	women.	Results	from	
previous	 studies	 investigating	 HDL-c	 and	 its	 anti-atherogenic	 properties	 in	 inflammatory	
conditions	 such	 as	 RA,	 indicate	 that	 HDL-c	 function	 deteriorates	 and	may	 even	 become	 pro-




results;	 the	 largest	 difference	 between	 RA	 patients	 and	 controls	 was	 found	 in	 HDL2-c	
concentrations,	and,	 consequently,	 the	HDL2-c:HDL3-c	 ratio	was	 lower	 in	 this	group.	This	 fact	
might	translate	into	an	impaired	RCT,	one	of	the	crucial	anti-atherogenic	mechanisms	involving	
HDL-c.	The	RCT	 relies	on	 the	quantity	of	both	HDL2-c	and	HDL3-c.	Several	enzymes,	 including	
cholesterylester	 transfer	 protein	 (CETP)	 may	 affect	 HDL2-c	 and	 HDL3-c	 concentrations,	 by	
lowering	them.[13]	Interestingly,	higher	CETP	concentrations	have	been	previously	indicated	in	
RA	patients	providing	 a	possible	 explanation	 for	 the	decreased	HDL2-c	 levels	 observed	 in	our	
study.[31]	 Lower	HDL2-c	 levels	may	 impair	 RCT	 in	 these	 patients,	 contributing	 to	 accelerated	






























to	 induce	 an	 increase	 in	 the	 risk	 of	 CVD,	 although	modest,	 supposedly	 due	 to	 a	 decrease	 in	
endogenous	 estrogen.[36-38]	 Nevertheless,	 it	 is	 unlikely	 that	 serum	 estrogen	 decisively	
contributed	 to	 the	 differences	 in	 HDL2-c	 observed	 in	 the	 present	 study,	 as	 it	 has	 been	
demonstrated	to	be	unaltered	 in	RA	women.[39]	Alternatively,	some	differences	 in	RA-related	
parameters	between	men	and	women	may	have	contributed	to	this	result.	In	line	with	that,	we	
observed	 that	 RA	women	 in	 this	 study	 had	 longer	 disease	 duration	 and	 higher	mean	 disease	
activity.	 However,	 there	 is	 inconsistent	 evidence	 of	 a	 certain	 influence	 of	 cumulative	 disease	
activity	on	the	lipid	profile	in	RA	patients.	We	have	previously	shown	that	disease	duration	is	not	




modest	 association	 between	 DAS28	 and	 HDL2-c	 concentration	 and	 no	 apparent	 relationship	
between	 DAS28	 and	 HDL3-c	 concentrations.	 For	 each	 1.0	 increment	 of	 the	 DAS28,	 HDL2-c	
decreased	by	0.06	mmol/L.	 If	disease	activity	 in	a	patient	 increases	 from	a	very	 low	 to	a	high	
DAS28	 score	 by	 3.1	 points,	 from	 2.0	 to	 5.1,	 theoretically	 the	 HDL2-c	 concentration	 would	




Due	 to	 the	 limited	 number	 of	 RA	 patients	 who	 were	 investigated,	 we	 were	 unable	 to	 find	
consistent	differences	between	the	various	treatment	strategies	regarding	HDL	subfraction	levels.	
This	is	an	interesting	issue	to	pursue	in	future	research.		
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become	a	priority	 in	 the	periodic	evaluation	of	 every	RA	patient.	Atherogenic	 index	has	been	
suggested	to	be	less	susceptible	to	disease	activity	variation	during	large	periods	of	time,	making	
him	more	attractive	to	be	used	in	CVD	risk	prediction	in	this	group	of	patients	as	compared	to	
individual	 lipids	 concentrations.	 Nevertheless,	 inflammation	 may	 negatively	 impact	 the	 anti-













such	 as	 dyslipidemia,	 hypertension,	 smoking,	 and	 physical	 inactivity.[3]	 Consequently,	 factors	
leading	or	deriving	 from	chronic	 inflammation	have	been	 suggested	 to	be	 responsible	 for	 the	
augmented	 CVD	 risk.[4–6]	 However,	 no	 such	 factor	 is	 proved	 to	 definitively	 confirm	 this	
hypothesis.	Recently,	several	studies	have	suggested	that	CVD	risk	assessment	in	RA	patients	can	
be	 improved	 solely	 by	 focusing	 on	 the	 traditional	 risk	 factors.	 Impaired	during	 the	periods	 of	





is	 applied	 as	 recently	 recommended.[9]	 Despite	 its	 limitations,	 the	 study	 emphasizes	 the	
possibility	of	suboptimal	therapy	of	traditional	risk	factors	in	RA	patients,	providing	a	means	of	
reducing	 CVD	 risk	 in	 RA.	 Furthermore,	 inflammation	 may	 alter	 traditional	 CVD	 risk	 factors	
including	 the	 lipid	 pattern,	 by	 augmenting	 concentration	 and	 composition	 level.[10,	 11]	 This	
observation	has	recently	led	to	the	concept	of	“smaller	slice	of	a	bigger	pie,”	which	emphasizes	
that	due	to	the	presence	of	chronic	 inflammation,	the	relative	contribution	of	these	factors	to	
overall	 CVD	 risk	 in	 RA	 is	 diﬀerent	 than	 in	 the	 general	 population.	 All	 these	 data	 suggest	 that	
despite	the	progresses	made	in	the	past	years,	traditional	CVD	risk	factors	such	as	dyslipidemia	
are	not	yet	entirely	understood	and	appropriately	managed	in	patients	with	RA.	Traditionally,	the	















in	 chronic	 inflammatory	 conditions,	 HDL-c	 anti-atherogenic	 properties	 (i.e.,	 antioxidant,	




development	 of	 atherosclerosis	 and	 CVD	 in	 RA	 patients.	 Recent	 recommendations	 for	 the	
treatment	of	RA	propose	a	tight	control	of	disease	activity	to	achieve	rapid	remission	in	the	early	
disease	stage.	Controlling	the	inflammatory	process	is	likely	to	favorably	impact	CVD	risk.	In	line	
with	 this,	 new	 therapeutic	 strategies	 have	 been	 recently	 elaborated,	 encouraging	 the	 use	 of	
aggressive	 anti-rheumatics,	 including	 biologicals,	 earlier	 in	 the	 course	 of	 disease.[7]	 The	
consequence	will	be	that	an	increasing	number	of	RA	patients	will	be	treated	in	the	future	with	
these	drugs.	Appropriate	knowledge	about	their	eﬀects	on	cardiovascular	risk	factors,	including	
lipid	 pattern,	 would	 therefore	 be	 of	 great	 importance.	 Several	 previous	 publications	 have	
addressed	 the	 eﬀects	 of	 biologicals	 on	 the	 lipid	 profile,	 concentrating	 on	 individual	 lipid	
levels/changes.	However,	important	questions	regarding	the	overall	atherogenic	capacity	of	the	













(c)	 values	 of	 total	 cholesterol	 (TC),	 HDL-c,	 and	 atherogenic	 ratio’s	 taken	 before	 and	 after	
treatment.	The	search	was	further	restricted	to	English	language	full-text	articles.	Studies	were	
manually	selected	by	two	authors	(CP,	EA)	by	screening	the	title,	keywords,	and	abstract,	using	
the	eligibility	 criteria.	 If	possibly	eligible,	 full-text	 articles	were	 retrieved	and	 judged	using	 the	
eligibility	criteria.	The	inclusion	of	articles	was	determined	by	consensus.	
Data	Presentation.		
Due	 to	 the	 heterogeneity	 of	 study	 populations,	 type	 of	 treatment,	 dosages,	 follow-up	 time,	
outcome	 measures,	 and	 statistical	 analysis,	 a	 meta-analysis	 was	 not	 performed.	 Hence,	 a	
narrative	summary	of	the	results	is	provided.	The	primary	summary	measure	used	to	compare	
results	was	 the	diﬀerence	 in	AI	 for	 short-term	 studies	 (<6	months)	 and	 long-term	 studies	 (>6	






In	 total,	 there	were	105	 records	 identified.	Of	 them,	4	were	excluded	because	 they	were	not	
written	 in	 English,	 5	were	 case	 reports,	 56	were	 oﬀ	 topic,	 3	were	 themselves	 reviews,	 and	 4	
studies	investigated	less	than	ten	RA	patients	(see	inclusion	criteria).	At	the	end	of	the	selection	
procedure,	 33	 full-text	 articles	met	 the	 eligibility	 criteria	 and	were	 considered	 for	 this	 paper	
(figure	 1).	 Of	 the	 33	 studies,	 the	 vast	 majority	 concerned	 anti-TNF	 users,	 usually	 infliximab,	
adalimumab,	 and	 etanercept,[11,	 14–32]	 8	 studies	 concerned	 tocilizumab	 (including	 three	
randomized	 clinical	 trials),[21,	 33–39]	 and	 5	 studies	 investigated	 rituximab	 eﬀects	 on	 lipids	































further	 confirmed	by	a	 recent	 study	 in	50	RA	patients	 receiving	adalimumab:	AI	baseline—16	
Mediators of Inflammation 3
105 articles
33 articles
Exclusion: n = 72
• 56 out-off topic
• 3 reviews
• 5 case reports
• 4 not English
• 4 (N < 10)
Figure 1: Flowchart.
3.1.1. Short-Term Studies. Short-term studies demonstrate
primarily significant antiatherogenic changes, particularly in
TC and HDL levels, whereas TG and LDL oncentrations
often remain unchang d. Interestingly and f importance
for our present paper, changes in the atherogenic index
(TC :HDL) and other ratios (LDL :HDL, ApoB : ApoA-1)
have also been noticed. Our group found a significant
decrease of approximately 8% in both LDL :HDL and
the TC :HDL ratio after two weeks of treatment with
adalimumab in a group of 33 RA patients as compared to
placebo [24]. Our results have been further confirmed by
a recent study in 50 RA patients receiving adalimumab: AI
baseline—16 weeks was 3.33 (0.93) versus 3.15 (0.85), P =
0.034 [32]. A significant decrease in the apoB : apoA-1 ratio
has been also reported (P = 0.014). A trend towards a
more pronounced eﬀect on HDL in the responders group
has been noticed together with an association with disease
activity changes (r = −0.31, P = 0.03). Similar results have
been reported by Jamnitski et al., who found a significant
decrease in the ApoB : ApoA-1 ratio over a period of 3
months [19] in 292 RA patients receiving TNF blockade.
Interestingly, this change has been found only in good and
moderate EULAR responders. Nevertheless, some further
studies reported opposite results (Table 1). Following 45 RA
patients treated with infliximab during a period of almost
6 months, our group reported a significant increase in the
TC :HDL ratio [11] at the end of this period. These findings
were supported by Dahlqvist et al. [17], who reported an
increase of 8% and 9% in the LDL :HDL and TC :HDL ratio,
over the same time period in 52 RA patients treated with
infliximab. Other studies did not indicate any change in the
atherogenic index or other ratios within a period of 3 or
6 months of anti-TNF therapy [14, 16, 18, 21, 25, 26, 28,
30, 31], although individual lipid levels were often found to
increase in the initial months of treatment [25, 26, 30, 31].
Studying 56 patients with RA receiving infliximab for 30
weeks, Allanore et al. found no changes in the atherogenic
index despite a significant stable increase of HDL and TC.
They also noticed no relations between response to therapy
and lipid pattern modifications [15]. Similar findings have
been reported by Seriolo et al. in 34 consecutive RA patients
treated with various TNF blockers (n = 16 for etanercept,
n = 14 for infliximab, and n = 4 for adalimumab) for
24 weeks [26]. The authors reported however on a relation
between changes in HDL and disease activity (DAS28) by the
end of the study (r = −0.52, P < 0.01), without making
any reference to response rate. These findings are in line
with those from a previous study, indicating a correlation
between the decrease in disease activity and the increase in
HDL 6 weeks after therapy with infliximab has been initiated
[31]. This association remained after adjusting for changes in
prednisone dose, age, gender, and disease duration. Although
the mean atherogenic index did not change, changes in
DAS28 were significantly associated with changes in the
atherogenic index in the period 0 to 2 weeks. However, this
association disappeared when the whole study period (6
weeks) has been considered.
A few more studies should be mentioned, which did
investigate the eﬀects of TNF blockade on lipids pattern
in RA patients, however, without entirely fulfilling our
inclusion criteria. Several investigators pulled together data
fr m patients with RA and other inflammatory conditions
such as ankylosing spondylitis [20]. In this setting, they
found no changes in AI after 6 months of therapy with
infliximab. Other studies provided data only on individual
lipids without atherogenic index or other ratios [22, 27,
29]. Finally, in an elegant study, Gonzalez-Juanatey et al.
investigated endothelial function and atherogenic index in
a small group (N = 8) of RA patients who failed on
infliximab and were now treated with adalimumab. Besides
rapid improvement of endothelial function, a significant
decrease of the atherogenic index was observed at week 2
(3.30 ± 0.55) and at week 12 (3.28 ± 0.48) when compared
with baseline atherogenic index result (3.52± 0.50) (P value
for both comparisons = 0.012). This was associated with a
decrease in disease activity and inflammation status [45].
The apparent heterogeneity of these results may be due
to several factors. Firstly, it mostly concerns small-group
studies enrolling RA patients from diverse countries with a
distinctive health care system and lifestyle habits, including
physical activity (biking for the Dutch population) [11, 23–
25, 31, 32] and alimentation (fish-reach diet in Northern
Europe, Mediterranean diet in the Southern Europe) [14,
15, 17, 18, 20, 26, 28]. Secondly, a diﬀerence between the
anti-TNF agents may be present, leading to a more pro-
atherogenic profile in the case of infliximab [11, 17], with
milder eﬀects for adalimumab and etanercept [19, 24, 32].
Thirdly, gendermay also contribute to this heterogeneity, our
group reporting a more pronounced eﬀect on lipid pattern
in male RA patients. Accordingly, total cholesterol and HDL
increased more markedly 6 months after starting infliximab
(P < 0.04), translating into a tendency to increase of the
atherogenic index [25]. Finally, the response rate and the
degree of response to anti-TNF therapy is likely to impact
the changes in lipid profile. Though several studies have
addressed the association between changes in disease activity
or inflammatory status and changes in lipids concentrations,
only a few investigated the association between the latter
and response according to established criteria (EULAR/ACR)
[19, 25, 32]. These studies suggest that the atherogenic index
tends to increase more in nonresponders as compared to







in	 the	 responders	 group	 has	 been	 noticed	 together	 with	 an	 association	 with	 disease	 activity	
changes	(r	=	−0.31,	P	=	0.03).	Similar	results	have	been	reported	by	Jamnitski	et	al.,	who	found	a	
significant	decrease	in	the	ApoB:ApoA-1	ratio	over	a	period	of	3	months	[19]	in	292	RA	patients	
receiving	TNF	blockade.	 Interestingly,	 this	 change	has	been	 found	only	 in	good	and	moderate	










lipid	 pattern	 modifications.[15]	 Similar	 findings	 have	 been	 reported	 by	 Seriolo	 et	 al.	 in	 34	
consecutive	 RA	patients	 treated	with	 various	 TNF	blockers	 (n	 =	 16	 for	 etanercept,	 n	 =	 14	 for	





remained	 after	 adjusting	 for	 changes	 in	 prednisone	 dose,	 age,	 gender,	 and	 disease	 duration.	


























in	 disease	 activity	 or	 inflammatory	 status	 and	 changes	 in	 lipids	 concentrations,	 only	 a	 few	
investigated	 the	association	between	the	 latter	and	response	according	 to	established	criteria	
(EULAR/ACR).[19,	 25,	 32]	 These	 studies	 suggest	 that	 the	 AI	 tends	 to	 increase	 more	 in	 non-
responders	as	compared	to	responders,[25]	or	to	decrease	only	in	responders.[19,	32]	
Table	1.	Short-term	effects	of	anti-TNF	drugs	on	AI	and	other	ratios.		
Study		 Drug	 No	of	patients	 Duration		 Effect	
	 	 	 	 AI	 Other	ratios	
Popa	et	al.[24]	 ADA	 33	 	2	wk	 L	 LDL-c:HDL-c	
Wijbrandts	et	al.[32]	 ADA	 8	 16	wk	 L		 ApoB:ApoA-1	
Gonzalez-Juanatey	et	al.[45]	 ADA	 8		 12	wk	 L	 -	
Kume	et	al.[21]		 ADA/ETN	 42	 24	wk	 N	 -		
Seriolo	et	al.[26]	 ADA/ETN/IFX	 34	 24	wk	 N	 -		
Soubrier	et	al.[28]	 ADA/ETN/IFX	 29	 14	wk	 N	 ApoB:ApoA-1	
Jamnitski	et	al.[19]	 ETN	 292	 16	wk	 L	 ApoB:ApoA-1	
Allanore	et	al.[15]	 IFX	 56	 30	wk	 N	 LDL-c:HDL-c	
Popa	et	al.[1]	 IFX	 45	 24	wk	 H	 -	
Dahlqvist	et	al.[17]	 IFX	 52	 24	wk	 H	 -		
Popa	et	al.[25]	 IFX	 55	 24	wk	 H	 -	
Tam	et	al.[30]	 IFX	 19	 14	wk	 N	 LDL-c:HDL-c	
Vis	et	al.[31]	 IFX	 69	 6	wk	 N	 -	
Engvall	et	al.[18]	 IFX	 40	 14	wk	 -	 ApoB:ApoA-1	
Ajeganova	et	al.[14]	 ADA/ETN/IFX	 162	 24	wk	 -	 ApoB:ApoA-1	
Curtis	et	al.[16]	 Not	specified	 289	 8	wk	 L	 -	

















subgroup	 compared	 to	 the	non-responders,	 reaching	 significance	 in	 the	 case	of	ApoB:ApoA-1	







found	 a	 significant	 increase	 in	 the	 TC:HDL-c	 ratio	 in	 a	 group	 of	 55	 RA	 patients	 treated	 with	
infliximab:	9%	after	6	months	(P	=	0.02)	and	4%	after	12	months	(P	=	0.05).[25]	In	the	same	study,	
LDL-c:HDL-c	ratio	did	not	significantly	changed	over	time.	Peters	et	al.	 found	no	change	in	the	
ApoB:ApoA-1	 ratio	and	TC:HDL-c	 ratio,	 respectively,	 in	a	group	of	80	RA	patients	 treated	with	
infliximab	for	a	period	of	48	weeks.[23]	Interestingly,	they	observed	that	changes	in	prednisone	
dose	were	related	to	changes	in	HDL-c	and	TC,	with	a	relatively	greater	impact	on	HDL-c,	resulting	
in	 an	 inverse	 association	 between	 prednisone	 dose	 and	 AI	 (TC:HDL-c	 and	 ApoB:ApoA-1).[23]	
Finally,	 in	 a	 large	 study	 involving	 diﬀerent	 anti-TNF	 agents	 (infliximab,	 adalimumab,	 and	
etanercept),	 Ajeganova	 et	 al.	 found	 no	 changes	 in	 ApoB:ApoA-1	 ratio	 in	 all	 three	 subgroups	
according	to	the	drug,	12	months	after	therapy	has	been	initiated.[14]	Similar	results	have	been	
previously	reported	by	Engvall	et	al.,	who	observed	no	change	in	ApoB:ApoA-1	ratio	between	3	
months	and	2	years	of	 follow-up.[18]	Both	 studies	 report	no	data	on	TC:HDL-c	 index.	Despite	
apparent	discrepancy,	some	trends	maybe	depicted	when	analyzing	these	long-term	eﬀects	of	
anti-TNF	drugs	on	lipids	in	patients	with	RA.	These	trends	become	clearer	when	focusing	on	AI,	
which	demonstrates	 therefore	 to	be	 superior	 to	 individual	 lipid	 concentrations	 in	 this	 respect	
(Table	 2).	 Therapy	 with	 etanercept	 or	 adalimumab	 seems	 to	 have	 a	 positive	 impact	 on	 AI,	
although	this	improvement	does	not	always	reach	statistical	significance.[19,	32]	In	contrast,	the	
use	of	infliximab	may	worsen	lipid	ratios	on	the	long	term,[17,	25]	though	some	report	a	neutral	
eﬀect.[23]	 Nevertheless,	 a	 rapid	 and	 sustained	 control	 of	 disease	 activity	 as	 in	 the	 case	 of	
responders	would	be	associated	with	better	ratios	compared	to	non-responders,	even	in	those	
patients	 treated	 with	 infliximab.[23]	 Alternatively,	 the	 concomitant	 use	 of	 prednisone	 may	
influence	 AI.	 Given	 the	 prognostic	 value	 of	 these	 ratios	 for	 future	 CVD,	 it	 is	 likely	 that	 these	
changes	 are	 clinically	 relevant	 and	may	 contribute	 to	 the	 decreased	 incidence	 of	myocardial	
infarction	and	other	CVD	events	observed	with	anti-TNFα	treatment	in	RA.	
Anti-TNF	therapy	and	HDL-c	function	
The	 link	 between	 HDL-c	 and	 cardiovascular	 disease	 risk	 is	 far	 more	 complex	 than	 originally	
thought.	 This	may	 be	 explained	 by	 the	 inherent	 heterogeneity	 of	 HDL-c	 particles	 in	 terms	 of	
composition,	 structure,	 and	 biological	 function.	 Emerging	 evidence	 suggests	 that	 for	 instance	
small	 dense	 protein-rich	HDL3-c	 particles	 are	 less	 capable	 of	 protecting	 LDL	 against	 oxidative	
modification.[46]	This	has	led	some	to	propose	that	the	functionality	of	HDL-c	may	be	as	relevant	
as	plasma	levels	of	HDL-c	to	CVD	risk	assessment.[47,	48]	In	the	same	context,	a	number	of	studies	





chronic	 inflammatory	diseases,	 such	as	RA.	 In	 a	 study	on	48	RA	patients,	which	also	 included	














that	 infliximab	 is	able	to	 improve	HDL-c	anti-oxidative	capacity,	an	eﬀect	that	was	sustained	6	
months	after	anti-TNF	therapy	has	been	initiated.[11]	It	is	still	unclear	how	stable	these	eﬀects	
are	further	in	the	course	of	therapy	and	whether	they	are	solely	due	to	TNF	blockade	or	more	
likely	 to	 reflect	 the	overall	 inflammatory	 suppression	achieved	 in	 these	patients.	Recently,	we	
observed	 that	 HDL-c	 subfractions	 are	 modified	 in	 RA	 patients,	 especially	 in	 women,[51]	
reinforcing	again	the	importance	and	in	the	same	time	the	complexity	of	HDL-c	status	in	these	
patients	 with	 respect	 to	 their	 CVD	 risk.	 Whether	 anti-TNF	 drugs	 are	 able	 to	 restore	 this	
detrimental	HDL-c	profile	remains	a	subject	for	further	investigations.	
Table	2.	Long-term	effects	of	anti-TNF	drugs	on	AI	and	other	ratios.		
Study	 Drug	 No	of	patients	 Duration	 Effect	
	 	 	 	 AI	 Other	ratios	
Jamnitski	et	al.[19]	 ETN	 292	 1	year	 N	 ApoB:ApoA-1	
Wijbrandts	et	al.[32]	 ADA	 50	 1	year	 N	 ApoB:ApoA-1	
Dahlqvist	et	al.[17]	 IFX	 51	 2	years	 H	 -	
Popa	et	al.[25]	 IFX	 55	 1	year	 H	 LDL-c:HDL-c	
Peters	et	al.[23]	 IFX	 80	 1	year	 N	 ApoB:ApoA-1	
Ajeganova	et	al[14]	 ETN/ADA/IFX	 162	 1	year	 -	 ApoB:ApoA-1	
Engvall	et	al.[18]	 IFX	 18	 2	years	 -	 ApoB:ApoA-1	




Interleukin	 (IL6)	 is	 another	 cytokine	 that	 plays	 a	 key	 role	 in	 the	 pathogenesis	 of	 chronic	
inflammatory	diseases.	Recently,	 the	therapeutic	blockade	of	 its	 receptor	proved	to	eﬃciently	
suppress	disease	activity	in	patients	with	RA.[33–35,	37,	39]	Owing	to	the	increased	CVD	risk	and	




the	 lipid	 pattern	 as	 part	 of	 the	 safety	 analysis	 of	 the	 drug.	 An	 increase	 of	 individual	 lipid	














5%	 in	 the	 placebo	 group.	 A	 comparable	 ApoB:ApoA-1	 ratio	 between	 the	 groups	 have	 been	









an	observational	 study,	Kawashiri	et	al.	noticed	no	changes	 in	 the	ApoB:ApoA-1	and	TC:HDL-c	
ratio	despite	an	increase	of	individual	lipids	in	a	small	group	of	RA	patients	treated	with	TCZ	for	







low	 number	 of	 patients	 enrolled	 in	 each	 group	 (approximately	 20).	 Overall,	 the	 present	




















There	 were	 few	 studies	 investigating	 the	 eﬀects	 of	 newer	 biologicals	 on	 lipids	 pattern	 in	 RA	
patients.	Rituximab,	a	B-cell	depletion	drug,	targeting	the	CD20	positive	B	lymphocytes,	has	been	
so	 far	been	scarcely	 investigated	with	regards	to	 its	eﬀects	on	AI	and	HDL-c	composition.	 In	a	
small	group	of	RA	patients,	Gonzalez-Juanatey	et	al.	investigated	for	the	first	time	the	eﬀects	of	
rituximab	on	 lipid	parameters.[40].	The	authors	have	 found	a	slight,	nonsignificant	 increase	 in	













±	 0.32	 g/L	 (P=0.06,	 follow-up	 of	 12	 months),	 respectively.	 The	 ratio	 ApoB:ApoA-1	 remained	
relatively	stable	and	did	not	change	significantly	over	the	study	period.	The	TC,	HDL-c,	and	their	
ratio	 (AI)	 have	 been	 not	 assessed.	 Interestingly,	 the	 authors	 found	 no	 associations	 between	
ApoB:ApoA-1	 ratios	 and	markers	 of	 disease	 activity,	 therefore	 sustaining	 our	 hypothesis	 that	
ratios	are	less	susceptible	to	changes	in	disease	activity	and	thus	they	are	probably	better	suited	









revealed	 that	 these	 changes	 were	 only	 present	 in	 the	 subgroup	 of	 responders.	 There	 is	 no	





























of	 these	 studies	 is	 often	 too	 short	 to	 include	 CVD	 events.	 Sometimes	 possible	 confounding	
variables	were	not	properly	accounted	 for	as	changes	 in	 lipid	 levels	often	were	not	a	primary	
outcome,	for	instance	in	the	majority	of	tocilizumab	studies.		
In	conclusion,	we	suggest	that	AI	and	HDL-c	function	are	more	suitable	parameters	of	lipid	profile	
as	 determinants	 of	 CVD	 risk	 in	 patients	with	RA,	 and	perhaps	 for	 other	 chronic	 inflammatory	
diseases	including	lupus,	psoriatic	arthritis,	and	ankylosing	spondylitis.	The	eﬀects	of	biologicals	
on	 these	 parameters	 depend	 on	 the	 response	 rate,	 concomitant	 prednisone	 use,	 duration	 of	
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rates	 of	 approximately	 25%.[1]	 Cardiovascular	 disease	 (CVD)	 represents	 the	 leading	 cause	 of	
death	in	RA,	accounting	for	approximately	50%	of	all	excess	mortality.[2]	The	excess	risk	of	CVD	
cannot	be	completely	explained	by	traditional	risk	factors	alone.[3]	Growing	evidence	supports	
the	 notion	 that	 inﬂammatory	 and	 immune	 mechanisms	 underline	 atherosclerosis.[4,	 5]	 It	 is	
hypothesized	that	chronic	systemic	inﬂammation	in	RA	represents	a	disease	related	risk	factor,	
accounting	for	extra	cardiovascular	(CV)	risk.[6]	Recent	studies	have	investigated	the	link	between	
the	 presence	 of	 inﬂammatory	 markers	 used	 to	 determine	 disease	 activity	 in	 RA,	 such	 as	
erythrocyte	sedimentation	rate	(ESR)	and	C-reactive	protein	(CRP),	and	the	development	of	CVD.	
CRP	has	been	indicated	as	a	predictor	for	(accelerated)	atherosclerosis.[7,	8]	ESR	and	CRP	have	
also	 been	 associated	 with	 CVD	 in	 RA	 and	 polyarthritis.[9–12]	 Atherosclerotic	 plaques	 in	 the	





the	 ‘smaller	 slice	 of	 a	 larger	 pie’	 concept	 in	which	 traditional	 CVD	 risk	 factors	 have	 a	 smaller	
contribution	to	CVD	risk	 in	RA	patients	 than	 in	 the	general	population.[6]	The	genotype	of	RA	
patients	 may	 also	 be	 of	 interest,	 potentially	 contributing	 to	 unfavourable	 lipid	 patterns	 and	
accelerated	 atherosclerosis.[20,	 21]	 Although	 a	 growing	 body	 of	 pathophysiological	 evidence	






over	 10	 years	 has	 been	 indicated	 as	 a	 risk	 factor	 for	 CVD	 in	 the	 European	 League	 Against	




Therefore,	 the	objectives	of	 the	present	 study	are	 (1)	 to	 investigate	 the	 relationship	between	









cohort.	 Patients	 were	 included	 at	 diagnosis	 of	 RA	 (baseline)	 in	 the	 outpatient	 clinic	 of	 the	















surgery,	 percutaneous	 coronary	 intervention	 and	 percutaneous	 transluminal	 coronary	
angioplasty.	Both	fatal	and	non-fatal	events	were	included.	Deaths	due	to	CVD	were	veriﬁed	from	





initial	 anti-rheumatic	 treatment	 and	 treatment	 with	 biological	 DMARDs.	 The	 time-averaged	
DAS28	score	was	calculated	by	taking	the	area	under	the	curve	of	the	DAS28	score	of	the	total	
follow-up	period	divided	by	the	follow-up	period.	Baseline	data	regarding	CVD	risk	factors	were	
















(VAS,	 mm)	 and	 diabetes	 at	 baseline	 (Y/N),	 treatment	 for	 CVD	 risk	 factors	 (Y/N),	 initial	 anti-







stopped	at	 the	 time	of	event,	or	was	censored	after	at	 the	 latest	after	10	years	of	event-free	
follow-up.	For	the	second	group	(group	2),	patients	were	selected	(again)	if	they	had	a	follow-up	
>10	years	and	were	free	of	CVD	up	until	that	point.	Patient	time	stopped	at	the	time	of	event	or	
















1	versus	33%	 in	group	2.	A	 total	of	154	CVD	events,	of	which	16	were	 fatal,	were	 registered,	
including	64	cases	of	acute	coronary	syndrome,	19	cases	of	stable	angina	pectoris,	30	cases	of	


















Age	(years),	mean±SD	 54±13.8	 62±9.7	 55±8.7	 <.001	
Sex	(female),	N(%)	 571	(67)		 63	(56)	 23	(56)	 0.97	
DAS28	 5.0±1.3	 5.4±1.3	 5.5±1.3	 0.83	
			SJC,	median	(P25-P75)	 9	(5–13)	 10	(6–15)	 11	(6–15)		 0.60	
			TJC,	median	(P25-P75)	 6	(2–11)	 8	(3–13)	 8	(3–13)	 0.97	
			ESR	(mm/h),	median	(P25-P75)	 30	(16–49)	 35	(18–48)	 39	(15–60)	 0.45	
			VAS	(mm),	median	(P25-P75)	 46	(27–59)	 50	(31–65)	 47	(31–60)	 0.37	
Rheumatoid	factor	(positivity),	N(%)	 664	(78)		 93(82)		 35	(85)		 0.65	
Initial	anti-rheumatic	treatment	 	 	 	 	
			Methotrexate,	N(%)	 135	(16)	 28	(25)	 3	(7)	 <.001	
			Sulfasalazine,	N(%)	 525	(61)	 69	(61)	 31	(76)	 0.09	
			Other,	N(%)	 195	(23)	 29	(26)	 7	(17)	 0.27	
Smoking,	N(%)	 256	(30)	 45	(40)	 16	(39)	 0.93	
BMI	(weight[kg]/height[m]2),	mean±SD	 23.7±6.8	 27±4.0	 25±3.3	 0.10	
Diabetes,	N(%)	 29	(3.4)	 11	(10)	 1	(2)	 0.14	
SBP	(mmHg),	mean±SD	 145±25	 155±24	 148±20	 0.10	
TC	(mmol/L),	mean±SD	 5.9±2.4	 5.2±1.4	 5.5±1.4	 0.27	
HDL-c	(mmol/L),	mean±SD	 1.5±0.6	 1.2±0.3	 1.4±0.4	 <.001	
TC:HDL-c	ratio	(mmol/L),	mean±SD	 4.2±0.9	 4.5±1.2	 4.0±0.8	 0.01	
CVD	prevention,	N(%)†	 129	(15.1)	 30	(27)	 11	(27)	 0.97	
i. P-value	for	the	difference	between	RA	patients	with	a	CVD	event	before	and	after	10	years	of	
disease	duration.	








If	 the	 risk	 of	 CVD	 would	 increase	 as	 disease	 duration	 increases,	 the	 cumulative	 survival	 and	
(expected)	 hazard	 lines	would	 show	a	 curve	 upwards	 as	 time	progresses.	 After	 correction	 for	
confounders	(table	2),	the	curves	did	not	change	(not	shown).	The	results	from	the	Kaplan-Meier	
survival	analysis	in	which	the	risk	of	CVD	during	the	first	10	years	of	disease	duration	(group	1)	












	 Estimate	 SE	 Exp(B)	 p-value	 95%	CI	
	 	 	 	 	 Lower	 Upper	
Age	(years)	 0.049	 0.008	 1.051	 <.001	 1.035	 1.067	
Smoking	(Y/N)	 0.424	 0.174	 1.528	 0.015	 1.087	 2.149	
BMI	(weight[kg]/height[m]2)	 0.065	 0.018	 1.067	 <.001	 1.030	 1.105	
HDL-c	(mmol/L)	 −.664	 0.211	 0.515	 0.002	 0.340	 0.912	
Diabetes	(Y/N)	 1.050	 0.312	 2.857	 0.001	 1.549	 5.268	
Time-averaged	DAS28	 0.430	 0.081	 1.537	 <.001	 1.312	 1.802	
Bioloigical	ever	(Y/N)	 −.538	 0.227	 0.584	 0.018	 0.374	 0.912	











Overall	 there	 was	 a	 difference	 in	 survival	 distributions	 between	 patients	 with	 low	 (<3.2),	
the main independent variable. Age, sex, smoking (Y/N), BMI
(weight (kg)/height(m)2), systolic blood pressure (mmHg), TC
(mmol/L), HDL-c (mmol/L), DAS28 and diabetes at baseline (Y/N),
RF status (positive/negative) and initial antirheumatic treatment
(methotrexate, sulfasalazine or other), treatment with methotrexate
ever (Y/N), treatment with biological ever (Y/N) were considered as
possible confounders.
Missing values on variables were imputed using multiple
imputation analysis with ﬁve repetitions.
RESULTS
Patient characteristics and CV events
In total, 855 patients were included, comprising 9959 patient
years. Patients had me n±SD disease duration of 11.7±6.1 years.
Patient characteristics at baseline are presented in table 1 for the
whole group and separately for patients with a CVevent within the
ﬁrst 10 years following disease onset and with a CV event after
more than 10 years. In group 1, 76% of patients were treated with
MTX compared with 73% in group 2, and 30% were treated with
a biological in group 1 versus 33% in group 2. A total of 154 CV
events, of which 16 were fatal, were registered, including 64 cases
of acute coronary syndrome, 19 cases of stable angina pectoris, 30
cases of strokes, 15 cases of TIAs, 21 cases of PAD and 5
Figure 1 Diseas duration until CV event or censoring in rheumatoid arthritis patients from the 1985 Nijmegen inception cohort. Cumulative
survival of cardiovascular disease (CVD) or event-free patients and the cumulative hazard are depicted on the y-axis of panels (A) and (B),
respectively. Time to event or censoring (disease duration) is depicted on the x-axis. As disease duration increases, the relative increase in CV risk
remains similar, resulting in a linear survival (A) and hazard (B) curve.
Table 2 Effect of disease duration on the risk of cardiovascular
disease; results of the Cox proportional hazards model with disease
duration until event or censoring as the time variable
Variable Estimate SE Exp (B) p Value
95% CI
Lower Upper
Sex (male) 0.618 0.173 1.856 <0.001 1.322 2.604
Age (years) 0.049 0.008 1.051 <0.001 1.035 1.067
Smoking (Y/N) 0.424 0.174 1.528 0.015 1.087 2.149
BMI (weight (kg)/
height (m)2)
0.065 0.018 1.067 <0.001 1.030 1.105
HDL-c (mmol/L) −0.664 0.211 0.515 0.002 0.340 0.912
Diabetes (Y/N) 1.050 0.312 2.857 0.001 1.549 5.268
Time-averaged
DAS28
0.430 0.081 1.537 <0.001 1.312 1.802
Biological ever (Y/
N)
−0.538 0.227 0.584 0.018 0.374 0.912
MTX ever −0.336 0.187 0.715 0.072 0.496 1.031
Cox proportional hazards regression model with disease duration until event or
censoring as the time variable. Corrected for the confounders shown.
BMI, body mass index; DAS28, 28 joint disease activity score; HDL-c, high-density
lipoprotein cholesterol; MTX, methotrexate.
Figure 2 Survival distribution for the group of patients at risk for
cardiovascular disease (CVD) before 10 years of disease duration (group 1)
and patients still at risk for CVD after 10 years (group 2). Cumulative
survival of CVD is depicted on the y-axis, and time to a CV event or
censoring (disease duration) is depicted on the x-axis.
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	 Estimate	 SE	 Exp(B)	 p-value	 95%	CI	
	 	 	 	 	 Lower	 Upper	
Crude	model		 	 	 	 	 	 	
		Time-averaged	DAS28	 0.271	 0.073	 1.311	 <.001	 1.135	 1.514	
Adjusted	model	 	 	 	 	 	 	
		Time-averaged	DAS28	 0.281	 0.092	 1.325	 0.002	 1.106	 1.588	
		Sex	(male)	 0.675	 0.173	 1.964	 <.001	 1.399	 2.759	
		Age	(years)	 0.047	 0.008	 1.048	 <.001	 1.033	 1.065	
		BMI	(weight[kg]/height[m]2)	 0.090	 0.013	 1.094	 <.001	 1.066	 1.123	
		RF	(positive)	 0.300	 0.224	 1.349	 0.182	 0.869	 2.095	
		DAS28	at	baseline	 0.114	 0.073	 1.120	 0.118	 0.971	 1.292	






the main independent variable. Age, sex, smoking (Y/N), BMI
(weight (kg)/height(m)2), systolic blood pressure (mmHg), TC
(mmol/L), HDL-c (mmol/L), DAS28 and diabetes at baseline (Y/N),
RF status (positive/negative) and initial antirheumatic treatment
(methotrexate, sulfasalazine or other), treatment with methotrexate
ever (Y/N), treatment with biological ever (Y/N) were considered as
possible confounders.
Missing values on variables were imputed using multiple
imputation analysis with ﬁve repetitions.
RESULTS
Patient characteristics and CV events
In total, 855 patients were included, comprising 9959 patient
years. Patients had a mean±SD disease duration of 11.7±6.1 years.
Patient characteristics at baseline are presented in table 1 for the
whole group and separately for patients with a CVevent within the
ﬁrst 10 years following disease onset and with a CV event after
more than 10 years. In group 1, 76% of patients were treated with
MTX compared with 73% in group 2, and 30% were treated with
a biological in group 1 versus 33% in group 2. A total of 154 CV
events, of which 16 were fatal were regist ed, including 64 cases
of acute coronary syndrome, 19 cases of stable angina pectoris, 30
cases of strokes, 15 cases of TIAs, 21 cases of PAD and 5
Figure 1 Disease duration until CV event or censoring in rheumatoid arthritis patients from the 1985 Nijmegen inception cohort. Cumulative
survival of cardiovascular disease (CVD) or event-free patients and the cumulative hazard are depicted on the y-axis of panels (A) and (B),
respectively. Time to event or censoring (disease duration) is depicted on the x-axis. As disease duration increases, the relative increase in CV risk
remains similar, resulting in a linear survival (A) and hazard (B) curve.
Table 2 Effect of disease duration on the risk of cardiovascular
disease; results of the Cox proportional hazards model with disease
duration until event or censoring as the time variable
Variable Estimate SE Exp (B) p Value
95% CI
Lower Upper
Sex (male) 0.618 0.173 1.856 <0.001 1.322 2.604
Age (years) 0.049 0.008 1.051 <0.001 1.035 1.067
Smoking (Y/N) 0.424 0.174 1.528 0.015 1.087 2.149
BMI (weight (kg)/
height (m)2)
0.065 0.018 1.067 <0.001 1.030 1.105
HDL-c (mmol/L) −0.664 0.211 0.515 0.002 0.340 0.912
Diabetes (Y/N) 1.050 0.312 2.857 0.001 1.549 5.268
Time-averaged
DAS28
0.430 0.081 1.537 <0.001 1.312 1.802
Biological ever (Y/
N)
−0.538 0.227 0.584 0.018 0.374 0.912
MTX ever −0.336 0.187 0.715 0.072 0.496 1.031
Cox proportional hazards regression model with disease duration until event or
censoring as the time variable. Corrected for the confounders shown.
BMI, body mass index; DAS28, 28 joint disease activity score; HDL-c, high-density
lipoprotein cholesterol; MTX, methotrexate.
Figure 2 Survival distribution for the group of patients at risk for
cardiovascular disease (CVD) before 10 years of disease duration (group 1)
and patients still at risk for CVD after 10 years (group 2). Cumulative
su i al of CVD is depicted on the y-axis, nd time to a CV event or
censoring (disease duration) is depicted on the x-axis.
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for	 their	 first	CV	event	after	10	years.	 Pathophysiological	data	have	delivered	 support	 for	 the	
revascularisation procedures. Missing values ranged from 0.1% for
RF to 10.3% for smoking at baseline.
Disease duration and the risk of CVD
The linearity of both the survival and the proportional hazard
curve shows that the cumulative risk increased with a similar
rate as disease duration increased and that the risk per year
remained constant (ﬁgure 1A); also the hazard for CVD
remained similar as disease duration increased (ﬁgure 1B). If the
risk of CVD would increase as disease duration increases, the
cumulative survival and (expected) hazard lines would show a
curve upwards as time progresses. After correction for confoun-
ders (table 2), the curves did not change (not shown).
The results from the Kaplan–Meier survival analysis in which
the risk of CVD during the ﬁrst 10 years of disease duration (group
1) was compared with the risk of CVD after 10 years of disease
duration (group 2) show similar survival distributions that did not
differ signiﬁcantly between groups, with p=0.82. The survival dis-
tributions are presented in ﬁgure 2, showing overlapping curves.
Disease activity and the risk of CVD
The mean±SD time-averaged DAS28 was 3.6±1.1. The results of
the Cox proportional hazard regression with the time-averaged
DAS28 as the main independent variable are presented in table 3.
After correction for confounders, the time-averaged DAS28 had a
signiﬁcant effect on the risk of CVD (p=0.002). With every point
the DAS28 increases, the hazard for CVD increases with 0.281.
Overall there was a difference in survival distributions between
patients with low (<3.2), moderate (3.2–5.1) and high (>5.1)
DAS28 over time (p=0.028). The survival curve of patients with a
consistently high disease activity, that is, a time-averaged DAS28
>5.1, was the lowest (ﬁgure 3). After correction for confounders,
this group (DAS28 >5.1) did not have a signiﬁcantly different
effect on CV risk compared with the <3.2 group (p=0.074).
Time-averaged ESR was not signiﬁcantly associated with CVD
(p=0.805) (data not shown).
DISCUSSION
According to the results of this study, disease duration did not
appear to affect the risk of CVD in patients with RA.
Furthermore, our data showed that mean RA disease activity
over the course of the disease (time-average DAS28) may con-
tribute to the risk of CVD.
The survival distribution for CVD was linear as disease duration
increased. Speciﬁcally the shape (linearity) of the survival curves
during the ﬁrst 10 years of RA and during the years thereafter was
very similar, and the survival distributions were not signiﬁcantly
different. If CV risk would increase in patients with long-standing
disease, the survival distribution curve would be expected to bend
upwards as time progresses. The EULAR recommendations include
disease duration >10 years as a risk factor for CVD, but the evi-
dence for this choice is limited.23 In a study by Gabriel et al1 in
which survival trends in the RA population were investigated, it
Table 3 Effect of disease activity on the risk of cardiovascular
disease; results of the Cox proportional hazards model




Time-averaged DAS28 0.271 0.073 1.311 <0.001 1.135 1.514
Adjusted model
Time-averaged DAS28 0.281 0.092 1.325 0.002 1.106 1.588
Sex (male) 0.675 0.173 1.964 <0.001 1.399 2.759
Age (years) 0.047 0.008 1.048 <0.001 1.033 1.065
BMI (weight (kg)/
height (m)²)
0.090 0.013 1.094 <0.001 1.066 1.123
RF (positive) 0.300 0.224 1.349 0.182 0.869 2.095
DAS28 at baseline 0.114 0.073 1.120 0.118 0.971 1.292
Biological ever (Y/N) −0.609 0.217 0.544 0.005 0.355 0.832
Results shown of the Cox proportional hazards regression analysis for the crude
model without correction for confounders and for the adjusted model that is
corrected for the confounders shown.
BMI, body mass index; DAS28, 28 joint disease activity score; RF, rheumatoid factor;
MTX, methotrexate.
Figure 3 Survival distributions for rheumatoid arthritis patients divided into three groups based on the time-averaged 28 joint disease activity
score (<3.2, 3.2–5.1, >5.1). Cumulative survival of cardiovascular disease (CVD) is depicted on the y-axis, and time to a CV event or censoring is
depicted on the x-axis.
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notion	 of	 disease	 duration	 as	 risk	 factor	 for	 CVD,	 as	 it	 has	 been	 reported	 that	 (accelerated)	
atherosclerosis	appears	to	be	more	severe	in	RA	patients	with	established	disease.[22]	However,	
this	 cross-sectional	 association	 with	 a	 surrogate	 marker	 has	 not	 been	 shown	 to	 translate	 in	
increased	risk	for	actual	CVD.	Also,	patients	with	RA	appear	to	be	more	prone	to	plaque	instability	




time	 increases	 CVD	 risk.	 Interestingly,	 ESR	 did	 not	 appear	 to	 significantly	 affect	 CVD	 risk.	
Additional	research	is	necessary	to	further	investigate	the	relationship	between	individual	DAS28	
components	and	CVD	risk.	Different	patient	groups	divided	based	on	disease	activity	(<3.2,	3.2–





of	 disease	 activity[30]	 as	we	have	 shown	 that	 there	was	no	difference	 in	 the	 level	 of	 disease	
activity	or	 the	number	of	patients	with	 low	to	moderate	 levels	of	disease	activity	between	RA	












the	 recent	 introduction	 of	 biological	 DMARDs,	 may	 affect	 CVD	 risk.	 Initial	 anti-rheumatic	
treatment	and	treatment	with	MTX	or	a	biological	during	follow-up	were	included	in	the	analysis	
and	proved	to	be	confounders.	The	widespread	introduction	of	biologicals	may	lead	to	an	overall	
decrease	 in	 disease	 activity	 levels	 in	 the	 RA	 population	 and	 to	more	 effective	 suppression	 of	
systemic	 inflammation	 in	 individual	 RA	 patients.	We	 did	 not	 investigate	 the	 effect	 of	 specific	














misclassification	 could	 lead	 to	 bias.	 However,	 patients	 enrolled	 in	 this	 cohort	 are	 seen	 and	





confirmed.	 Therefore,	 missed	 events	 or	 misclassification	 of	 CVD	 events	 was	 considered	 an	
unlikely	source	of	bias	in	this	study.	
In	conclusion,	our	results	show	that	disease	duration	does	not	appear	to	independently	affect	the	
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(≤3.2),	 moderate	 (3.2-5.1),	 and	 high	 (>5.1)	 disease	 activity	 were	 used.	 The	 effect	 of	 disease	
activity	on	CVD	risk	was	analyzed	using	Cox-proportional	hazards	regression	with	DAS28	as	a	time-






















lead	 to	 the	 formation	 of	more	 severe	 plaques	 in	 RA	 patients.[9-12]	 In	 comparison	 to	 healthy	
controls	and	RA	patients	in	remission,	RA	patients	with	active	disease	seem	to	have	more	unstable	
plaques,	which	increases	the	probability	of	CVD.[13]	Consequently,	the	level	of	disease	activity	
has	been	 implicated	as	 a	 contributing	 factor	 to	 the	development	of	CVD,	 and	 conversely,	 the	
absence	of	inflammation	or	clinical	remission	may	be	associated	with	a	reduced	risk	of	CVD	in	RA.	
The	results	 from	a	case-control	study	showed	no	evidence	that	disease	activity	over	 time	was	
associated	with	occurrence	of	myocardial	 infarction.[14]	 In	 a	 longitudinal	 study	by	our	 group,	
results	 indicated	 that	 very	high	disease	 activity	over	 time	or	high	disease	 activity	 at	RA	onset	
significantly	contributes	to	the	risk	of	CVD	in	RA.[15]	In	a	recent	study	by	Myasoedova	et	al	it	was	
demonstrated	that	particularly	exposure	to	disease	activity	flare-ups	and	increased	cumulative	




disease	activity	 could	 therefore	have	a	beneficial	effect	on	CVD	 risk.[18]	 It	 is	unclear	whether	
clinical	 remission	needs	 to	be	achieved	 in	order	 to	eliminate	or	diminish	 the	possible	harmful	
effects	of	systemic	inflammatory	activity	or	if	stable	low	disease	activity	over	time	is	sufficient.	







cohort.	 Patients	 were	 included	 at	 diagnosis	 of	 RA	 (baseline)	 in	 the	 outpatient	 clinic	 of	 the	
departments	 of	 rheumatology	 of	 the	 Radboud	 University	Medical	 Centre	 (since	 1985)	 or	 the	











cohort	 and	 the	 date	 of	 a	 first	 CVD	 event	 or	 censoring	 were	 included	 in	 the	 analysis,	 with	 a	
maximum	of	10	years	of	follow-up.	
Data	collection		
































isolated	 missing	 measurement,	 the	 mean	 of	 the	 measurement	 prior	 and	 the	 measurement	
following	 the	missing	 value	was	 used.	 If	more	 than	 1	 consecutive	measurement	was	missing,	
subjects	were	censored.	To	repeat	the	analysis	using	a	more	readily	interpretable	reflection	of	
	 101	
disease	 activity,	 the	 next	 step	 was	 to	 analyze	 the	 time-averaged	 DAS28	 as	 main	 dependent	
variable	 using	 conventional	 Cox-proportional	 hazard	 regression	 analysis.	 The	 time-averaged	
DAS28	was	calculated	by	taking	the	area	under	the	curve	of	the	DAS28	score	of	the	total	follow-
up	 period	 divided	 by	 the	 follow-up	 period.	 The	 analysis	 was	 performed	 again	with	 the	 time-
averaged	DAS28	as	a	binary	variable	(time-averaged	DAS28	≤3.2	or	2.6).		
In	all	analyses,	sex	and	age	were	included	in	the	model	as	confounders	by	default.	The	following	
potential	 confounders	 were	 considered;	 current	 smoking	 status,	 baseline	 measurements	 of	
systolic	 blood	pressure	 (mmHg),	 diastolic	 blood	pressure	 (mmHg)	 and	body	mass	 index	 (BMI)	
(weight	[kg]/height	[m]²),	hypertension	(physician	diagnosis),	diabetes	mellitus	(Type	I	and	II),	TC	
(mmol/L),	 HDL-c	 (mmol/L),	 family	 history	 of	 premature	 CVD,	 use	 of	 statins	 and	 use	 of	 anti-












of	 CVD,	 patients	 with	 a	 follow-up	 time	 <12months	 or	 patients	 with	 2	 or	 less	 DAS28	
measurements,	873	patients	were	included	in	the	analyses.	A	total	of	99	RA	patients	developed	
a	first	CVD	event	during	their	first	10	years	of	follow-up.	The	following	fatal	and	non-fatal	first	




due	 to	 acute	 coronary	 syndrome	 (43%).	 Total	 follow-up	 time	 was	 4560	 patient	 years	 with	 a	






















Age	(years),	mean±SD	 54±14	 53±14	 62±9	 <.001	
Sex	(female),	n	(%)	 574(66)	 524(68)	 50(51)	 0.001	
Currently	smoking,	n	(%)	 272(31)	 235(30)	 69(40)	 0.156	
BMI	(weight[kg]/Height[m]²),	mean±SD	 26±4	 25±4	 26±4	 0.016	
Systolic	blood	pressure	(mmHg),	mean±SD	 146±24	 145±24	 153±24	 0.002	
Diastolic	blood	pressure	(mmHg),	mean±SD	 84±12	 83±12	 86±11	 0.026	
Hypertension	n	(%)	 120(14)	 94(12)	 26(26)	 <.001	
Anti-hypertensives,	n(%)	 134(15)	 110(14)	 24(24)	 0.009	
Total	Cholesterol	(mmol/L),	mean±SD	 5.2±1.2	 5.2±1.2	 5.3±1.4	 0.448	
HDL-Cholesterol,	mean±SD	 1.3±0.3	 1.3±0.3	 1.2±0.3	 0.040	
TC:HDL-c	ratio,	mean±SD	 4.1±1.0	 4.1±1.0	 4.4±1.0	 0.013	
LDL-Cholesterol,	mean±SD	 3.2±1.1	 3.1±1.0	 3.2±1.2	 0.357	
Lipid	lowering	agents,	n	(%)	 30(3.4)	 23(3)	 7(7)	 0.035	
Diabetes	mellitus	n	(%)	 37(4)	 29(4)	 8(8)	 0.044	
Family	history	of	CVD,	n	(%)	 265(30)	 232(30)	 33(33)	 0.494	
Rheumatoid	factor	(positivity),	n	(%)		 654(75)	 576(74)	 78(79)	 0.345	
Anti-CCP	(positivity),	n(%)	 554(64)	 493(64)	 61(62)	 0.686	
DAS28,	mean±SD	 5.0±1.3	 4.9±1.3	 5.4±1.3	 0.001	
CRP,	median	(IQR)	 14(2-40)	 13(2-38)	 21(3-47)	 0.083	













variable,	 the	 results	 showed	 that	 disease	 activity	 had	 a	 significant	 effect	 on	 CVD	 risk	 after	
correction	 for	 confounders	 (table	 2,	 panel	 B),	 indicating	 that	 CVD	 risk	 increases	 as	 DAS28	
increases	during	follow-up.	The	hazard	ratio	(HR),	in	table	2B	of	1.179	can	be	interpreted	as	an	
increase	in	risk	of	18%	if	the	DAS28	is	one	point	higher.	Table	2,	panel	C	shows	the	results	from	





Table	 2.	 Cox-proportional	 hazard	 regression	 analysis	 with	 time	 to	 first	 CVD	 event	 as	 the	 primary	
outcome	and	time-dependent	DAS28	as	the	primary	independent	variable,	before	(panel	A)	and	after	













time-averaged	 DAS28	 of	 0.7	 and	 7.3	 respectively.	 The	 mean±SD	 time-averaged	 DAS28	 was	
significantly	 lower	 in	 the	 non-event	 group	 compared	 to	 the	 event	 group	 (3.5±1.1	 vs.	 3.9±1.2	
respectively,	with	p<0.001).	Results	 from	the	conventional	Cox-proportional	hazard	 regression	
analysis	with	time-averaged	DAS28	as	the	main	independent	variable,	showed	a	significant	effect	
	 Beta	 p-value	 HR	 95%	CI	for	Exp	(B)	
Lower	 Upper	
Panel	A:	Crude	model	 	 	 	 	 	
Time	dependent	covariate	(DAS28)		 0.113	 0.119	 1.120	 0.972	 1.290	
Age		 0.064	 <.001	 2.010	 1.344	 3.005	
Gender	 0.698	 0.001	 1.066	 1.047	 1.085	
	 	 	 	 	
Panel	B:	Corrected	model	 	 	 	 	
Time	dependent	covariate	(DAS28)	 0.165	 0.032	 1.179	 1.014	 1.370	
Age	 0.062	 <.001	 1.064	 1.044	 1.084	
Gender	 0.725	 0.001	 2.065	 1.365	 3.123	
Hypertension	baseline	 1.036	 <.001	 2.818	 1.673	 4.745	
HDL-C	 -.736	 0.043	 0.466	 0.222	 0.977	
CV	medication†	 -.515	 0.026	 0.597	 0.379	 0.940	
DAS28	baseline	 0.034	 0.687	 1.035	 0.877	 1.220	
	 	 	 	 	
Panel	C:	Corrected	model	 	 	 	 	
Time	dependent	covariate	(DAS28<3.2)	 -.431	 0.044	 0.650	 0.427	 0.989	
Age	 0.064	 <.001	 1.066	 1.046	 1.087	
Gender	 0.736	 0.001	 2.088	 1.372	 3.177	
Hypertension		 0.977	 <.001	 2.656	 1.547	 4.559	
HDL-C	 -1.113	 0.009	 0.329	 0.142	 0.758	
LDL-c	 0.177	 0.097	 1.193	 0.969	 1.470	
CV	medication†	 -.541	 0.022	 0.582	 0.366	 0.925	











0.45-1.38).	 These	 results	 are	 in	 accordance	 with	 the	 results	 of	 the	 first	 set	 of	 analyses	 that	
included	a	time-dependent	covariate.	
Table	 3.	 Cox-proportional	 hazard	 regression	 analysis	 with	 time	 to	 first	 CVD	 event	 as	 the	 primary	
outcome	and	remission	(yes/no)	as	the	time-dependent	variable,	before	(panel	A)	and	after	(panel	B)	
correction	for	confounders.	
	 Beta	 p-value	 HR	 95%	CI	for	Exp	(B)	
Lower	 Upper	
Panel	A:	Crude	model	 	 	 	 	 	
Time	dependent	covariate	(remission)	 -.211	 0.358	 0.810	 0.516	 1.270	
Age		 0.064	 0.001	 1.066	 1.047	 1.086	
Gender	 0.665	 0.001	 1.945	 1.304	 2.901	
	 	 	 	 	 	
Panel	B:	correcte	model	 	 	 	 	
Time	dependent	covariate	(remission)	 -.395	 0.096	 0.673	 0.426	 1.066	
Age	 0.063	 <.001	 1.065	 1.045	 1.085	
Gender	 0.680	 0.001	 1.974	 1.306	 2.984	
Hypertension		 0.971	 <.001	 2.640	 1.540	 4.528	
HDL-C	 -.772	 0.039	 0.462	 0.222	 0.963	














patients	 with	 a	 time-averaged	 DAS28	 <2.6	 and	 a	 time	 averaged	 DAS28	 between	 2.6	 and	 3.2	


































averaged	 DAS28.	 Survival	 distributions	 differ	 significantly	 (p<0.001).	 Cumulative	 survival	 of	 CVD	 is	
depicted	on	the	y-axis	and	time	to	a	CVD	event	or	censoring	is	depicted	on	the	x-axis.	




Figure 1. Survival distribution (time to first CV event) for categories of time-averaged DAS28. Survival 
distributions differ significantly (p0.027). Cumulative survival of CVD is depicted on the y-axis and time to a 
CV event or censoring is depicted on the x-axis. 
 
Figure 2. Survival distribution (time to first CV event) for low (≤3.2) and moderate to high (>3.2) time-
averaged DAS28. Survival distributions differ significantly (p<0.001). Cumulative survival of CVD is depicted 
on the y-axis and time to a CV event or censoring is depicted on the x-axis. 
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Figure 1. Survival distribution (time to first CV event) for categories of time-averaged DAS28. Survival 
distributions differ significantly (p0.027). Cumulative survival of CVD is depicted on the y-axis and time to a 
CV event or censoring is depicted on the x-axis. 
 
Figure 2. Survival distribution (time to first CV event) for low (≤3.2) and moderate to high (>3.2) time-
averaged DAS28. Survival distributions differ significantly (p<0.001). Cumulative survival of CVD is depicted 
on the y-axis and time to a CV event or censoring is depicted on the x-axis. 
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	 Beta	 p-value	 HR	 95%	CI	for	Exp	(B)	
Lower	 Upper	
Panel	A:	Crude	model	 	 	 	 	 	
Time-averaged	DAS28	 0.383	 <0.001	 1.466	 1.204	 1.786	
Age		 0.060	 <0.001	 1.062	 1.043	 1.082	
Gender	 0.848	 <0.001	 2.336	 1.549	 3.521	
	 	 	 	 	
Panel	B:	full	model	 	 	 	 	
Time-averaged	DAS28	 0.468	 <0.000	 1.597	 1.279	 1.994	
Age	 0.056	 <0.001	 1.057	 1.037	 1.077	
Gender	 0.954	 <0.001	 2.595	 1.712	 3.933	
Hypertension	baseline	 0.920	 <0.001	 2.508	 1.566	 4.018	
DAS28	baseline	 -.048	 0.587	 0.953	 0.802	 1.133	
	 	 	 	 	
Panel	D:	full	model	 	 	 	 	
Time-averaged	DAS28	binary;	(≤3.2)	 -.630	 0.007	 0.533	 0.337	 0.843	
Age	 0.058	 <0.001	 1.060	 1.040	 1.080	
Gender	 0.803	 <0.001	 2.231	 1.491	 3.339	
Hypertension	baseline	 0.882	 <0.001	 2.417	 1.506	 3.879	











Previous	 studies	 have	 demonstrated	 that	 inflammation	 contributes	 to	 accelerated	
atherosclerosis.[25-27]	 Atherosclerosis	 in	 turn	 is	 an	 intermediate	 in	 causing	 non-bleeding	 CV	
events.	Concordantly,	the	results	of	this	study	show	that	active	disease	in	RA	is	associated	with	
an	 increased	 risk	of	developing	CV	events.	 Furthermore,	when	 looking	at	 the	overall	 trend	of	
disease	 activity	 during	 follow-up,	 those	 patients	who	were	 able	 to	 achieve	 and	maintain	 low	
disease	activity	over	time	appear	to	have	a	significantly	lower	risk	of	CVD	than	patients	with	more	











study.	By	contrast,	Myasoedova	et	al.	have	 shown	 in	a	 recent	 study	 that	particularly	bouts	of	
uncontrolled	high	disease	activity	are	associated	with	a	higher	risk	of	CVD.[16]	A	study	by	Solomon	





to	 remission,	 another	 study	 demonstrated	 that	 RA	 patients	 in	 remission,	 defined	 as	 Clinical	
Disease	Activity	Index,	or	CDAI	≤2.8	had	significantly	lower	levels	of	CVD	risk	markers	compared	





may	 form	a	 subgroup	within	 the	RA	population	 that	 is	particularly	at	 risk	 for	developing	CVD,	
significantly	contributing	to	the	excess	CVD	risk	in	this	population.		
In	 the	analysis	of	 the	effect	of	 low	disease	activity	or	clinical	 remission	on	CVD	risk,	 there	are	







Immortal	 time	 bias	 can	 be	 avoided	 by	 integrating	 the	 changes	 in	 exposure	 status	 in	 the	
analysis.[30]	 Consequently,	 for	 this	 study	 a	 Cox-proportional	 hazards	 regression	 with	 a	
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ability	 was	 comparable	 across	 the	 original,	 recalibrated	 and	 adapted	 SCORE	 algorithms.	 The	
Hosmer–Lemeshow	 test	 results	 indicated	 that	 all	 three	 algorithms	 provided	 poor	 model	 fit	
(p<0.05)	for	the	Nijmegen	and	external	validation	cohort.	The	adapted	SCORE	algorithm	mainly	




sufficient	 improvement	 in	 risk	 prediction	 of	 future	 CVD	 in	 RA	 to	 serve	 as	 an	 appropriate	




In	 rheumatoid	 arthritis	 (RA),	 cardiovascular	 disease	 (CVD)	 morbidity	 and	 mortality	 are	
increased.[1,	2]	Inflammation	may	contribute	to	the	increased	risk	of	CVD,[3–10]	suggesting	that	
inflammatory	markers	should	be	incorporated	in	CVD	risk	prediction	models	for	RA.	For	example,	










(SCORE)	 algorithm,	 have	 been	 developed	 for	 use	 in	 the	 general	 population.[18–20]	 Their	
performance	 in	 patients	 with	 RA	 appears	 to	 be	 suboptimal.[21–23]	 Therefore,	 it	 has	 been	
suggested	that	CVD	risk	algorithms	based	solely	on	traditional	risk	factors	may	not	be	suited	for	















Data	 from	 the	 Nijmegen	 early	 RA	 inception	 cohort	 were	 used	 for	 this	 study.	 Patients	 were	
included	at	diagnosis	of	RA	(baseline)	in	the	outpatient	clinic	of	the	Departments	of	Rheumatology	
of	 the	Radboud	University	Medical	Centre	 (since	1985)	or	 the	Maartenskliniek	 (since	1990)	 in	














In	 addition	 to	 the	 traditional	 risk	 factors	 used	 in	 the	 SCORE	 algorithm,	 potential	 RA-specific	






















weights)	of	 the	predictors	originally	 included	 in	SCORE	 (current	 smoking	 status,	 systolic	blood	





national	 guideline	 for	 cardiovascular	 risk	management	 and	we	 used	 this	 version.[30]	 For	 the	
adaptation	of	the	SCORE	algorithm,	other	potential	predictors	were	added	to	the	existing	SCORE	
variables.	 Variables	 with	 a	 significance	 level	 p<0.1	 in	 univariate	 Cox	 proportional	 hazards	
regression	analysis	were	evaluated	in	a	multivariate	Cox	proportional	hazard	regression	analysis.	
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In	 the	multivariate	analysis,	 traditional	CVD	risk	 factors	 included	 in	 the	SCORE	algorithm	were	
predetermined	to	stay	 in	 the	model	and	other	new	predictors	were	 included	at	a	deliberately	
more	liberal	p	value	of	<0.2.	The	following	potential	risk	factors	were	considered:	body	mass	index	
(BMI;	weight	(kg)/	height	(m)2),	hypertension	(physician	diagnosis),	diabetes	mellitus	(type	I	and	





and	the	non-event	group,	was	 tested	using	 the	concordance	statistic	 (c-statistic)	and	the	area	









The	 performance	 of	 the	 original,	 recalibrated	 and	 adapted	 SCORE	 algorithms	 concerning	 the	
prediction	of	 fatal	 and	non-fatal	CVD	was	also	analyzed	 in	external	 cohorts,	 consisting	of	400	




A	 total	of	141	patients	with	a	 follow-up	 time	of	<18	months	or	documented	CVD	prior	 to	RA	
diagnosis	were	excluded,	leaving	1016	patients	for	analysis	(table	1).	During	follow-up,	103	first	























Age	(years),	mean±SD	 54±13	 53±14	 62±10	 <.001	
Sex	 (	female),	n(%)	 674	(66.3)	 620	(67.9)	 54	(52.4)	 0.002	
Currently	smoking,	 n(%)	 313	(30.8)	 280	(30.7)	 40	(38.8)	 0.133	
BMI	 (weight(kg)/height(m)
2
),	mean±SD	 25.5±4.3	 25.5±4.3	 26.9±4.1	 0.004	
Systolic	blood	 pressure	(mm	Hg),	mean±SD	 146±24	 145±24	 156±25	 <.001	
Diastolic	blood	pressure	(mm	Hg),	mean±SD	 84±11	 84±12	 87±9	 0.004	
Hypertension	(	physician	diagnosis)	 	 	 	 	
			At	baseline,	n(%)	 144	(14.2)	 117	(12.8)	 27	(26.2)	 <.001	
			During	follow-up,	 n(%)	 260	(25.6)	 220	(24.1)	 40	(38.8)	 0.002	
Antihypertensives,	 n(%)	 159	(15.6)	 130	(14.2)	 29	(28.2)	 <.001	
Total	cholesterol	 (mmol/L),	mean±SD	 5.2±1.3	 5.2±1.3	 5.2±1.3	 0.743	
HDL-cholesterol,	mean±SD	 1.3±0.3	 1.3±0.3	 1.2±0.3	 0.018	
TC:HDL-c	 ratio,	mean±SD	 4.2±1.0	 4.1±1.1	 4.5±1.2	 0.037	
LDL-cholesterol,	mean±SD	 3.2±1.1	 3.2±1.0	 3.2±1.1	 0.526	
Non-HDL	 cholesterol,	mean±SD	 3.9±1.1	 3.9±1.1	 4.0±1.2	 0.296	
Lipid-lowering	agents,	n(%)	 40	(3.9)	 33	(3.6)	 7	(6.8)	 0.191	
Diabetes	mellitus	 	 	 	 	
			At	baseline,	n(%)	 44	(4.3)	 36	(3.9)	 8	(7.8)	 0.121	
			During	follow-up,	 n(%)	 84	(8.3)	 69	(7.6)	 15	(14.6)	 0.024	
Family	history	 of	CVD,	n(%)	 312	(30.7)	 274	(30.0)	 38	(36.9)	 0.180	
Rheumatoid	 factor	 (	positivity),	 n(%)	 761	(74.9)	 680	(74.5)	 81	(78.6)	 0.427	
Anti-CCP	 (	positivity),	n(%)	 643	(63.3)	 592	(64.8)	 68	(66)	 0.803	
DAS28,	mean±SD	 4.9±1.3	 4.9±1.3	 5.3±1.3	 0.002	
Swollen	joint	count,	median		 (IQR)	 8	(5–12)	 8	(5–12)	 9	(5–13)	 0.104	
Tender	joint	count,	median		 (IQR)	 5	(3–10)	 5	(3–10)	 7	(2–12)	 0.057	
ESR,	median	(IQR)	 25	(16–45)	 24	(16–45)	 35	(21–50)	 0.002	
VAS,	median	(IQR)	 41	(30–57)	 40	(29–56)	 48	(32–65)	 0.008	
CRP,	median	(IQR)	 16	(3–42)	 15	(3–41)	 26	(6–48)	 0.023	
HAQ,	median	(IQR)	 0.6	(0.3–1.1)	 0.6	(0.3–1.1)	 0.8	(0.3–1.1)	 0.054	
MTX	 treatment	ever,	n(%)	 555	(54.6)	 506	(55.4)	 49	(47.6)	 0.158	





iii. Anti-CCP,	anti-cyclic	citrullinated	peptide;	BMI,	body	mass	 index;	CRP,	C	 reactive	protein;	
CVD,	 cardiovascular	 disease;	 DAS28,	 28-joint	 disease	 activity	 score;	 DMARDs,	 disease-
modifying	 antirheumatic	 drugs;	 ESR,	 erythrocyte	 sedimentation	 rate;	 HAQ,	 Health	

























Figure	1.	Receiver	operating	 	 characteristic	 (ROC)	curves	 	 for	the	original	 Systematic	 COronary	 Risk	Evaluation	
(SCORE)	 and	the	adapted	SCORE	 algorithms.	 Area	under	the	curve	 values	 were	(95%	CI)	 0.78	(0.74	 to	0.82)	
and	0.80	(0.76	to	0.84)	for	the	original	and	adapted	SCORE	 algorithm,	respectively.	
Calibration	
Patients	 were	 grouped	 into	 deciles	 based	 on	 ascending	 predicted	 CVD	 risk.	 In	 each	 of	 these	
groups	the	observed	number	of	CVD	events	was	compared	with	the	calculated	(expected)	risk	for	
CVD	 events.	 It	 appeared	 that	 when	 using	 the	 original	 SCORE	 algorithm,	 the	 CVD	 risk	 was	
underestimated	in	the	lower	and	middle	deciles	and	was	greatly	overestimated	in	the	top	decile	
(figures	2A	and	3A).	The	H–L	test	indicated	a	poor	model	fit	with	a	p	value	of	<0.001.	Next,	the	









were registered including 17 acute coronary events, ﬁve cases of
stroke, two c ses of HF a d wo cases of other CV death. Due
to missing values on non-traditional CVD risk factors, 24 events
were available for analysis related to the validation the adapted
SCORE algorithm. Missing values ranged from 0% to 5%
(DAS28). Discriminatory ability of the adapted SCORE algo-
rithm was inferior to the original SCORE algorithm with an
area under the curve of 0.76 (95% CI 0.68 o 0.84), 0.74 (0.66
to 0.83) for the original and adapted SCORE algorithm,
respectively. The H–L test indicated a poor model ﬁt for both
models with a p value of <0.001.
DISCUSSION
In RA, risk assessment by traditional CVD risk models such as
SCORE appears to be suboptimal.21 22 27 Therefore, the aim of
this study was to adapt the SCORE algorithm to improve the
accuracy of CVD risk estimates in patients with RA, by changing
the weights (recalibration) and by adding new variables (adapta-
tion). Unfortunately, recalibration and adaptation of the SCORE
algorithm with additional RA-speciﬁc CVD risk factors did not
lead to major improvements in the accuracy of CVD risk predic-
tion in patients with RA.
Several RA-speciﬁc predictors were considered and some of
them, such as high DAS28 at baseline, showed signiﬁcant pre-
dictive power. However, in the end the SCORE algorithm
adapted with RA-speciﬁc predictors showed a rather modest
improvement in discriminatory ability in comparison with the
original SCORE. Furthermore, the adapted SCORE algorithm
mainly improved overestimation of CVD risk in patients not
getting CVD and in the highest risk groups. Overestimation of
CVD risk may be harmful as patients receive unnecessary treat-
ment. However, overestimation of CVD risk mostly affected
intermediate-risk to high-risk patients, in which case overesti-
mation would only reafﬁrm treatment indication and would not
change the indication for treatment. Improvement of CVD risk
estimates in these patients therefore is less important for clinical
purposes. Much could be gained from improving the classiﬁca-
tion of patients with RA who later develop CVD (event cases)
into higher risk groups so these patients become eligible for pre-
ventive treatment. The adapted SCORE does not show a signiﬁ-
cant improvement in this area, leaving undetected high-risk
patients with RA at risk of being under treated. In general,
underestimation of CVD risk in RA appears to be the main
problem with the original SCORE as shown by us as well as by
others.21 27 Similar results have been reported for other CVD
risk calculators such as FRS.22 The FRS signiﬁcantly underesti-
mated CVD risk, especially in older patients and in patients
with positive RF and persistently elevated ESR. This indicates
that i RA disease severity and inﬂammation that are not
accounted for in current CVD risk algorithms may play a role.
However, our adaptation of the SCORE algorithm including
these variables did not solve the issue.
Figu e 1 Receiver operating characteristic (ROC) curves for the
original Systematic COronary Risk Evaluation (SCORE) and the adapted
SCORE algorithms. Area under the curve values were (95% CI) 0.78
(0.74 to 0.82) and 0.80 (0.76 to 0.84) for the original and adapted
SCORE algorithm, respectively.
Figure 2 Calibration plots. Probabilities depicted at the y axis, and the predicted probabilities depicted at the x axis as calculated by the original
Systematic COronary Risk Evaluation (SCORE) algorithm (A) and the adapted SCORE algorithm (B). A line was ﬁtted between the observed and
predicted probabilities of cardiovascular disease events using cubic spline.
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depicted	 at	 the	 x	 axis	 as	 calculated	 by	 the	 original	 Systematic	 COronary	 Risk	 Evaluation	 (SCORE)	












algorithms	were	 similar	 for	 the	majority	of	patients	 and	did	not	 lead	 to	a	 reclassification	 into	
another	risk	group	for	most	patients	(68%).	
were registered including 17 acute coronary events, ﬁve cases of
stroke, two cases of HF and two cases of other CV death. Due
to missing values on non-traditional CVD risk factors, 24 events
were available for analysis related to the validation the adapted
SCORE algorithm. Missing values ranged from 0% to 5%
(DAS28). Discriminatory ability of the adapted SCORE algo-
rithm was inferior to the original SCORE algorithm with an
area under the curve of 0.76 (95% CI 0.68 to 0.84), 0.74 (0.66
to 0.83) for the original and adapted SCORE algorithm,
respectively. The H–L test indicated a poor model ﬁt for both
models with a p value of <0.001.
DISCUSSION
In RA, risk assessment by traditional CVD risk models such as
SCORE appears to be suboptimal.21 22 27 Therefore, the aim of
this study was to adapt the SCORE algorithm to improve the
accuracy of CVD risk estimates in patients with RA, by changing
the weights (recalibration) and by adding new variables (adapta-
tion). Unfortunately, recalibration and adaptation of the SCORE
algorithm with additional RA-speciﬁc CVD risk factors did not
lead to major improvements in the accuracy of CVD risk predic-
tion in patients with RA.
Several RA-speciﬁc predictors were considered and some of
them, such as high DAS28 at baseline, showed signiﬁcant pre-
dictive power. However, in the end the SCORE algorithm
adapted with RA-speciﬁc predictors showed a rather modest
improvement in discriminatory ability in comparison with the
original SCORE. Furthermore, the adapted SCORE algorithm
mainly improved overestimation of CVD risk in patients not
getting CVD and in the highest risk groups. Overestimation of
CVD risk may be harmful as patients receive unnecessary treat-
ment. However, overestimation of CVD risk mostly affected
intermediate-risk to high-risk patients, in which case overesti-
mation would only reafﬁrm treatment indication and would not
change the indication for treatment. Improvement of CVD risk
estimates in these patients therefore is less important for clinical
purposes. Much could be gained from improving the classiﬁca-
tion of patients with RA who later develop CVD (event cases)
into higher risk groups so these patients become eligible for pre-
ventive treatment. The adapted SCORE does not show a signiﬁ-
cant improvement in this area, leaving undetected high-risk
patients with RA at risk of being under treated. In general,
underestimation of CVD risk in RA appears to be the main
problem with the original SCORE as shown by us as well as by
others.21 27 Similar results have been reported for other CVD
risk calculators such as FRS.22 The FRS signiﬁcantly underesti-
mated CVD risk, especially in older patients and in patients
with positive RF and persistently elevated ESR. This indicates
that in RA disease severity and inﬂammation that are not
accounted for in current CVD risk algorithms may play a role.
However, our adaptation of the SCORE algorithm including
these variables did not solve the issue.
Figure 1 Receiver operating characteristic (ROC) curves for the
original Systematic COronary Risk Evaluation (SCORE) and the adapted
SCORE algorithms. Area under the curve values were (95% CI) 0.78
(0.74 to 0.82) and 0.80 (0.76 to 0.84) for the original and adapted
SCORE algorithm, respectively.
Figure 2 Calibration plots. Probabilities depicted at the y axis, and the predicted probabilities depicted at the x axis as calculated by the original
Systematic COronary Risk Evaluation (SCORE) algorithm (A) and the adapted SCORE algorithm (B). A line was ﬁtted between the observed and
predicted probabilities of cardiovascular disease events using cubic spline.
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CVD	 (n	=	103)								 Adapted	 SCORE	 	 	 	
Original	SCORE																																						 	 <10%	 10-20%	 >20%	
	 <10%	 21	(20.4)	 2	(1.9)	 1	(1.0)	
	 10%–20%	 4	(3.9)	 9	(8.7)	 4	(3.9)	
	 >20%	 2	(1.9)	 13	(12.6)	 47	(45.6)	
No	CVD	(n	=	913)	 Adapted	SCORE	 	 	 	
Original	SCORE	 	 <10%	 10-20%	 >20%	
	 <10%	 570	(62.4)	 14	(1.5)	 2	(0.2)	
	 10%–20%	 66	(7.2)	 57	(6.2)	 14	(1.5)	





external	 validation	 (please	 see	 supplementary	 table	 S3	 for	 further	 details).	 Patients	 had	 a	
mean±SD	 follow-up	 of	 7.5±2.2	 years.	 A	 total	 of	 26	 first	 fatal	 or	 non-fatal	 CVD	 events	 were	
registered	including	17	acute	coronary	events,	ﬁve	cases	of	stroke,	two	cases	of		HF	and	two	cases	
of	other	CV	death.	Due	 to	missing	 values	on	non-traditional	CVD	 risk	 factors,	 24	events	were	
available	for	analysis.	Missing	values	ranged	from	0%	to	5%	(DAS28).	Discriminatory	ability	of	the	
adapted	SCORE	algorithm	was	 inferior	to	the	original	SCORE	algorithm	with	an	area	under	the	
















to	 the	 original	 SCORE.	 Furthermore,	 the	 adapted	 SCORE	 algorithm	 mainly	 improved		




Improvement	 of	 CVD	 risk	 estimates	 in	 these	 patients	 is	 therefore	 less	 important	 for	 clinical	
purposes.	Much	could	be	gained	from	improving	the	classiﬁcation	of	patients	with	RA	who	later	
develop	CVD	(event	cases)	into	higher	risk	groups	so	these	patients	become	eligible	for	preventive	
treatment.	 The	adapted	SCORE	does	not	 show	a	 signiﬁcant	 improvement	 in	 this	 area,	 leaving	
undetected	high-risk	patients	with	RA	at	risk	for	being	under	treated.	In	general,	underestimation	
of	CVD	risk	in	RA	appears	to	be	the	main	problem	with	the	original	SCORE	as	shown	by	us	as	well	
as	by	others.[21	27]	Similar	 results	have	been	 reported	 for	other	CVD	 risk	 calculators	 such	as	
FRS.[22]	The	FRS	signiﬁcantly	underestimated	CVD	risk,	especially	in	older	patients	and	in	patients	












both	 early	 and	 established	 RA	 from	 varying	 geographical	 areas.	 Conﬂicting	 results	 have	 been	
reported	with	regards	to	the	onset	of	the	increased	risk	of	CVD	in	patients	with	RA.[24,		35–38]	It	
may	prove	to	be	difﬁcult	to	develop	a	singular	CVD	risk	algorithm	that	can	be	applied	successfully	
in	 all	 RA	 populations	 across	 different	 countries.	 Furthermore,	 the	 	 baseline	 risk	 that	 	 was	
determined	 in	the	general	population	for	the	original	SCORE	was	also	 included	 in	the	adapted	
algorithm	and	this	may	contribute	to	systematic	underestimation	of	CVD	risk	by	this	algorithm.	
As	 the	 baseline	 risk	 for	 CVD	 is	 increased	 in	 an	 individual	 with	 RA	 compared	 to	 a	 healthy	
counterpart	of	similar	age	and	sex,[1,	2]	it	may	be	necessary	to	adapt	this	baseline	risk.	However,		
although		our	cohorts		are		among		the		largest		RA	cohorts		available		with	sufﬁcient	data	on	CVD	
risk	 factors	 and	 follow-up,	 the	 number	 of	 available	 patients	 with	 RA	 and	 CVD	 events	 in	 this	
individual	cohort	was	still	deemed	insufﬁcient	to	determine	a	reliable,	robust	baseline	risk	that	
could	 be	 extrapolated	 	 to	 other	 	 RA	 populations.	 Furthermore,	 the	 adapted	 SCORE	 algorithm	
developed	in	this	study	is	a	basic	revision	of	the	original	SCORE	including	all	traditional	CVD	risk	
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number	of	CVD	events	might	be	used	 to	develop	a	RA-speciﬁc	CVD	 risk	 algorithm	 taking	 into	
consideration	 other	 factors,	 most	 intuitively	 related	 to	 the	 disease	 pathogenesis	 and	
inﬂammation.	Alternatively,	additional	 investigations	such	as	carotid	ultrasound	may	provide	a	
substantial	 	 improvement	 	 of	 	 correct	 	 classiﬁcation	 	 of	 	 these	patients,	 even	when	using	 the	








	 B	 P-value	 OR	 95%	CI	for	OR	
	 	 		 	 Lower		 Upper	
SCORE	Recalibrated	<65	years	 	 	 	 	 	
Smoking	 0.341	 0.165	 1.406	 0.865	 2.285	
Systolic	blood	pressure	*	 0.019	 <0.001	 1.019	 1.011	 1.027	
TC:HDL-c	ratio*	 1.407	 0.004	 4.085	 1.574	 10.60	
	 	 	 	 	 	
SCORE	Recalibrated	>65	years		 	 	 	 	 	
Age*	 0.061	 <0.001	 1.063	 1.044	 1.082	
Sex	 0.570	 0.005	 1.769	 1.188	 2.634	
Smoking	 0.382	 0.148	 1.465	 0.867	 2.473	
Systolic	blood	pressure*	 0.008	 0.061	 1.008	 1.000	 1.017	
TC:HDL-ratio	 1.228	 0.011	 3.414	 1.324	 8.806	
	 	 	 	 	 	
SCORE	Adapted	 	 	 	 	 	
Smoking	 0.380	 0.115	 1.462	 0.909	 2.350	
Systolic	blood	pressure*	 0.012	 0.009	 1012	 1.003	 1.021	
TC:HDL-c	ratio*	 1.387	 0.006	 4.005	 1.488	 10.78	
BMI	 0.038	 0.068	 1.039	 0.997	 1.082	
Diabetes	at	baseline	 0.695	 0.068	 2.004	 0.949	 4.233	
Hypertension	at	baseline	 0.725	 0.003	 2.065	 1.273	 3.348	
DAS28	>5.1		 0.557	 0.006	 1.745	 1.170	 2.601	


























Age	(years),	mean±SD	 60±12.3	 69±9	 60±12	
Sex	(female),	n(%)	 393	(77)	 16	(62)	 377	(78)	
Smoking,	n(%)	 111	(22)	 4	(15)	 107	(22)	
BMI	(weight[kg]/Height[m]²),	mean±SD	 26.9±5.1	 26±3.5	 26.9±5.1	
Systolic	blood	pressure	(mmHg),	mean±SD	 144±23	 155±24	 143±22	
Diastolic	blood	pressure	(mmHg),	mean	±SD	 81±12	 81±12	 81±12	
Hypertension,	n(%)	 340	(66.5)	 23	(89)	 317	(65)	
Treated	with	anti-hypertensives,	n(%)	 162	(32)	 13	(50)	 149	(31)	
Total	Cholesterol	(mmol/L),	mean±SD	 5.5±1.2	 6.1±1.2	 5.4±1.2	
HDL-Cholesterol,	mean±SD	 1.7±0.5	 1.7±0.5	 1.7±0.5	
TC:HDL-c	ratio,	mean±SD	 3.6±1.1	 3.8±1.1	 3.5±1.1	
LDL-Cholesterol,	mean±SD	 3.2±1.2	 3.8±1.2	 3.2±1.1	
Treatment	with	statins/fibrates,	n(%)	 60	(12)	 3	(12)	 57	(12)	
Diabetes,	n(%)	 36	(7)	 1	(4)	 35	(7)	
Rheumatoid	factor	(positivity),	n(%)		 349	(68)	 18	(69)	 331	(68)	
Anti-CCP	(positivity),	n(%)	 319	(62)	 20	(77)	 299	(62)	
Disease	duration	at	baseline	(years),	mean±SD	 12.6±8.8	 18.2±11.5	 12.3±8.6	
DAS28,	mean±SD	 4.1±1.4	 3.9±1.4	 4.1±1.4	
				Swollen	joint	count,	median	(IQR)	 4	(1-7)	 2	(0-7)	 4	(1-7)	
				Tender	joint	count,	median	(IQR)		 3	(1-8)	 2	(1-6)	 3	(1-8)	
				ESR,	(IQR)	 17	(9-32)	 18	(10-36)	 17	(9-31)	
				VAS,	(IQR)	 40	(20-60)	 38	(20-60)	 40	(20-60)	
DAS28	>5.1,	n(%)	 113	(22)	 4	(15)	 109	(23)	
CRP,	median	(IQR)	 7	(3-16)	 8	(3-18)	 7	(3-16)	
HAQ,	median,	mean±SD	 1.3	(0.4-1.9)	 1.2	(0.3-2.1)	 1.3	(0.4-1.9)	
SCORE	original	(%),	median	(P25-P75)	 8.3	(2.7-25.6)	 32	(14-64)	 8	(3-24)	
SCORE	updated	(%),	median	(P25-P75)	 8.2	(2.7-19.9)	 23	(12-43)	 7	(2-19)	
i. BMI;	body	mass	index,	TC;	total	cholesterol,	HDL;	high	density	lipoprotein,	LDL;	low	density	
lipoprotein,	CVD;	cardiovascular	disease,	anti-CCP;	anti-cyclic	citrullinated	peptide,	DAS28;	































of	 death	 from	 cardiovascular	 disease	 in	 patients	with	 inﬂammatory	 polyarthritis:	 a	 ten-year	
followup	study	of	a	primary	care-based	inception	cohort.	Arthritis	Rheum.	2005;	52:	p	2293–9	
9. Wallberg-Jonsson	 S,	 Johansson	 H,	 Ohman	 ML,	 et	 al.	 Extent	 of	 inﬂammation	 predicts	













14. Dessein	 PH,	 Stanwix	 AE,	 Joffe	 BI.	 Cardiovascular	 risk	 in	 rheumatoid	 arthritis	 versus	
osteoarthritis:	 acute	 phase	 response	 related	 decreased	 insulin	 sensitivity	 and	 high-density	
lipoprotein	 cholesterol	 as	 well	 as	 clustering	 of	metabolic	 syndrome	 features	 in	 rheumatoid	
arthritis.	Arthritis	Res.	2002;	4:	R5	















21. Arts	 EEA,	 Popa	 CP,	 Den	 Broeder	 AA,	 et	 al.	 Performance	 of	 four	 current	 risk	 algorithms	 in	
predicting	cardiovascular	events	 in	patients	with	early	 rheumatoid	arthritis.	Ann	Rheum	Dis.	
2015;	74:	p	668–74	
22. Crowson	 CS,	Matteson	 EL,	 Roger	 VL,	 et	 al.	 Usefulness	 of	 risk	 scores	 to	 estimate	 the	 risk	 of	
cardiovascular	disease	in	patients	with	rheumatoid	arthritis.	Am	J	Cardiol.	2012;	110:	p	420–4	
23. Kawai	VK,	Chung	CP,	Solus	JF,	et	al.	The	ability	of	the	2013	ACC/AHA	cardiovascular	risk	score	to	
identify	 rheumatoid	 arthritis	 patients	with	high	 coronary	 artery	 calciﬁcation	 scores.	Arthritis	
Rheumatol.	2015;	67:	p	381–5.	
24. Peters	 MJ,	 Symmons	 DP,	 McCarey	 D,	 et	 al.	 EULAR	 evidence-based	 recommendations	 for	
cardiovascular	 risk	 management	 in	 patients	 with	 rheumatoid	 arthritis	 and	 other	 forms	 of	
inﬂammatory	arthritis.	Ann	Rheum	Dis.2010;	69:	p	325–31	
25. Gomez-Vaquero	 C,	 Corrales	 A,	 Zacarias	 A,	 et	 al.	 SCORE	 and	 REGICOR	 function	 charts	
underestimate	 the	cardiovascular	 risk	 in	Spanish	patients	with	 rheumatoid	arthritis.	Arthritis	
Res	Ther.	2013;	15:	R91	






28. Aletaha	D,	Neogi	T,	 Silman	AJ,	et	al.	Rheumatoid	arthritis	 classiﬁcation	criteria:	an	American	
College	 of	 Rheumatology/European	 League	 Against	 Rheumatism	 collaborative	 initiative.	
Arthritis	Rheum.	2010;	62:	p	2569–81		
29. Statistics	 Netherlands.	 Centre	 for	 Policy	 Related	 Statistics.	 http://wwwcbsnl/	 Date	 accessed	
February	 2013	 Nederlands	 Huisartsen	 Genootschap	 [The	 Dutch	 Collage	 of	 General	
Practictioners]	























































is	 a	 hallmark	 of	 RA,	 which	 has	 been	 a	 focal	 point	 of	 research	 investigating	 CVD	 risk	 in	 this	
population.	Whilst	 there	 are	 various	ways	 in	which	 systemic	 inflammation	 is	 hypothesized	 to	
increase	CVD	risk,	the	exact	mechanism	underlying	the	association	between	inflammation	and	
CVD	in	RA	remains	largely	unknown.	Evidence	supporting	the	application	of	(disease	specific)	CVD	
risk	management	 guidelines	 in	 RA	 is	 limited.	 It	 is	 unclear	 what	 strategy	 is	most	 effective	 for	
accurate	detection	of	RA	patients	at	risk	for	developing	CVD,	and	what	predictors	would	be	best	
suited	for	CVD	risk	estimation	in	RA.	This	information	is	of	importance	for	appropriate	allocation	
of	 preventative	 treatment,	 thus	 for	 the	 reduction	 of	 CVD	 morbidity	 and	 mortality	 in	 this	
population.	Therefore,	the	main	focus	of	this	thesis	was	on	CVD	risk	prediction	and	on	the	CVD	










Chapter	 3:	 Risk	 estimates	 by	 traditional	 CVD	 risk	 algorithms,	 when	 applied	 in	 RA	
population,	were	found	to	be	 less	accurate	compared	to	reports	 from	the	general	population.	





DMARDs	are	able	to	modulate	the	 lipid	profile	 in	RA.	 Interestingly,	these	changes	 in	 individual	
lipid	 levels	do	not	always	translate	 into	changes	 in	the	AI	or	are	not	sustained	 long	enough	to	
significantly	affect	 this	 ratio.	 Inflammation	may	also	diminish	 the	beneficial	effect	of	HDL-c	by	







individual	 RA	 patients.	 Disease	 activity	 on	 the	 other	 hand	 appears	 to	 augment	 CVD	 risk,	







it	 is	 not	 an	 appropriate	 alternative	 to	 the	 original	 SCORE.	However,	 risk	 estimation	 using	 the	
original	SCORE	algorithm	may	underestimate	CVD	risk	in	RA	patients.		
Cardiovascular	disease	risk	prediction	in	RA		







the	 predictive	 performance	 of	 four	 currently	 available	 CVD	 risk	 models,	 which	 are	 based	 on	
traditional	 risk	 factors,	 is	 not	 satisfactory.[Chapter	 3]	 Accordingly,	 the	 risk	 of	 future	 CVD	 is	















update	 of	 the	 EULAR	 recommendations	 for	 CVD	 risk	 management	 in	 the	 RA	 population	 still	
advocates	the	use	of	this	multiplication	factor	as	the	most	evidence	based	CVD	risk	algorithm	in	












associated	with	 the	 development	 of	 CVD.[2,	 6,	 7,	 20,	 21]	 The	 complexity	 of	 the	mechanisms	




levels	 in	 RA	 have	 been	 associated	 with	 insulin	 resistance.[22]	 In	 combination	 with	 reduced	
physical	activity	levels	this	may	lead	to	the	development	of	metabolic	syndrome;	a	collection	of	
risk	 factors	 for	 the	 development	 of	 CVD.[23,	 24]	 Furthermore,	 fluctuations	 in	 inflammatory	
activity	or	disease	activity	in	RA	patients	appear	to	affect	lipoproteins	levels.	The	AI	seems	to	be	
less	affected	and	more	stable,	rendering	it	a	more	suitable	determinant	for	CVD	risk.[Chapter	5]	






a	 result	 of	 the	 effects	 of	 systemic	 inflammation.[25-28]	Of	 note,	 these	 changes	 appear	 to	 be	
associated	with	an	increased	CVD	event	rate.	A	high	apolipoprotein	(apo)B/apoA1	ratio	was	found	




CVD	risk	 in	patients	with	active	disease	 [Chapter	4,	5]	Conversely,	anti-rheumatic	 therapies	 in	


























6	and	7	 these	 factors	were	 taken	 into	account.	Based	on	our	 research	 it	appears	 that	disease	
duration,	 or	 the	 time	 that	 disease	 activity	 exerts	 its	 influence,	 is	 not	 a	 strong	 independent	
predictor	 for	 future	 CVD	 in	 RA.[Chapter	 6]	 Disease	 activity	 however	 does	 appear	 to	 have	 a	
significant	effect	on	the	risk	of	CVD	which	seems	to	be	most	apparent	in	patients	who	are	more	




























significantly	 different	 from	 the	 risk	 profile	 in	 the	 general	 population.	 Simply	 adjusting	 or	
recalibrating	an	existing	CVD	risk	algorithm	does	not	seem	to	be	sufficient	as	it	does	not	result	in	
a	 significant	 improvement	 in	 the	accuracy	of	10-year	CVD	 risk	estimates	 [Chapter	8].	 The	 risk	
estimates	calculated	with	the	adjusted	SCORE	algorithm	did	correct	some	of	the	underestimation	
of	CVD	risk,	also	including	a	portion	of	RA	patients	who	would	otherwise	be	categorized	as	low	or	
intermediate	 CVD	 risk	 and	 who	 would	 therefore	 be	 unlikely	 to	 receive	 adequate	 preventive	





media	 thickness	 and	 presence	 and	 composition	 of	 atherosclerotic	 carotid	 plaques	 could	
contribute	 to	more	 accurate	 CVD	 risk	 prediction.	 Screening	 for	 asymptomatic	 atherosclerotic	
plaques	by	means	of	carotid	ultrasound	has	been	recommended	as	part	of	CVD	risk	assessment	






would	 be	 ineffective.	 In	 the	 2015/2016	 update	 of	 the	 EULAR	 recommendations	 for	 CVD	 risk	
management	the	authors	point	out	that	statins	appear	to	be	equally	effective	in	RA	patients.[19]	
Results	 from	 the	 Trial	 of	 Atorvastatin	 for	 the	 primary	 prevention	 of	 Cardiovascular	 Events	 in	
patients	with	Rheumatoid	Arthritis	(TRACE-	RA)	that	included	2986	RA	patients	with	7908	patient	
years	of	 follow-up	show	that	statins	are	safe	and	effective	for	use	 in	RA	patients.	A	significant	
reduction	 in	 LDL-c	 levels	was	 achieved	 in	 patients	 randomized	 to	 40mg	 of	 atorvastatin	 daily,	
compared	 to	 placebo.	 Also,	 a	 34%	 reduction	 in	 CVD	 events	was	 reported	 in	 the	 intervention	







RA	patients	have	an	 increased	 risk	of	CVD,	 and	 systemic	 inflammation	 is	 likely	 to	be	a	 crucial	
contributor	herein,	both	as	an	independent	risk	factor	and	by	modulating	other	traditional	CVD	
risk	 factors.	Currently	available	CVD	risk	algorithms	provide	suboptimal	 risk	estimates	 in	 these	
	 137	
patients,	which	may	lead	to	ineffective	allocation	of	preventive	measures.	A	disease	specific	CVD	
risk	 algorithm,	 tailored	 to	 the	 CVD	 risk	 profile	 of	 RA	 patients,	may	 provide	 a	 solution	 to	 this	
problem	although	a	 simple	adjustment	of	existing	 risk	algorithms	does	not	 seem	sufficient.	 In	






improved	 allocation	 of	 preventive	 care.	 Additionally,	 as	 disease	 activity	 appears	 to	 be	 an	
important	 addition	 to	 the	 CVD	 risk	 profile	 of	 RA	 patients,	 striving	 for	 tight	 control	 of	 disease	
activity	during	the	course	of	RA	is	of	 importance,	not	only	to	prevent	joint	damage	but	also	to	
reduce	the	risk	of	CVD.	Particularly	patients	with	severe	disease	activity	at	diagnosis	and/or	those	





systemic	 inflammation	on	CVD	risk,	 investigating	the	 long-term	effects	of	tight-control	on	CVD	
risk	and	to	continue	to	explore	the	potential	of	disease	specific	CVD	risk	factors	that	may	facilitate	
the	identification	of	high	risk	patients.	
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Patients	with	 rheumatoid	arthritis	 (RA)	have	an	 increased	 risk	of	 cardiovascular	disease	 (CVD)	





algorithm	that	 includes	disease	specific	 risk	 factors	was	developed	and	evaluated.	The	second	
objective	was	to	investigate	the	role	of	inflammation	in	the	CVD	risk	profile	of	RA	patients	and	to	















anti-atherogenic	 properties	 of	 HDL-c	 in	 RA	 patients.	 Altered	 function	 of	 HDL-c	 as	 a	 result	 of	



















in	 the	 accuracy	 of	 CVD	 risk	 estimates.	 A	 more	 rigorous	 approach	 for	 developing	 a	 CVD	 risk	

































en	 het	 risico	 op	 hart-	 en	 vaatziekten	 bij	 patiënten	met	 RA.	 Voor	 het	 verrichte	 onderzoek	 dat	





van	 lipoproteïnepartikels	 in	 het	 serum	 tijdens	 langdurige	 opslag	 een	 bescheiden	 effect	
geobserveerd	op	de	hoogte	van	de	gemeten	lipoproteïne	waardes.	Het	is	onwaarschijnlijk	dat	dit	
een	 significant	 effect	 heeft	 op	 schattingen	 van	 het	 cardiovasculair	 risico.	 Als	 volgende	 stap	
werden	vier	bestaande	cardiovasculaire	risicomodellen,	veel	gebruikt	in	de	algemene	populatie,	
in	 een	 RA-cohort	 geëvalueerd.	 Dit	 is	 besproken	 in	 Hoofdstuk	 3.	 Deze	 vier	 modellen	 bleken	




predictiemodel	 gericht	 op	 de	 RA-patiënt	 verder	 faciliteren.	 In	 dat	 opzicht	 is	 het	 met	 name	




controles.	 De	 compositie	 van	 HDL-c	 partikels	 lijkt	 onder	 invloed	 van	 ontstekingsactiviteit	 te	
veranderen,	wat	kan	bijdragen	aan	de	verminderde	anti-atherogene,	gunstige,	functie	van	HDL-
c.	 Een	 veranderde	 functie	 van	 HDL-c	 werd	 ook	 gerapporteerd	 door	 andere	 studies	 die	 zijn	
besproken	 in	 de	 systematische	 literatuur	 review	 in	 Hoofdstuk	 5.	 Daarnaast	 lieten	 resultaten	
gepresenteerd	in	dit	hoofdstuk	ook	zien	dat	disease	modifying	anti-rheumatic	drugs	(DMARDs)	
die	 ontstekingsactiviteit	 onderdrukken	 invloed	 lijken	 te	 hebben	 op	 het	 lipidenprofiel	 bij	 RA-
patiënten.	Deze	veranderingen	 leiden	echter	meestal	niet	 tot	significante	veranderingen	 in	de	
relatieve	 TC:HDL-c	 ratio,	 ofwel	 atherogenic	 index	 (AI).	 Gezien	 deze	 bevindingen	 lijken	 deze	
TC:HDL-c	 ratio	 en	 HDL-c	 functie	 meer	 geschikte	 parameters	 van	 het	 lipidenprofiel	 om	 te	
includeren	 in	 het	 cardiovasculair	 risicoprofiel	 van	 RA-patiënten.	 Naast	 een	 interactie	 tussen	
ontstekingsactiviteit	 en	 traditionele	 risicofactoren	 lijkt	 ontsteking	 ook	 als	 een	 onafhankelijke	
risicofactor	 te	werken.	 In	Hoofdstuk	 6	werd	 dit	 verder	 onderzocht	 door	 het	 effect	 van	 zowel	
	 149	
ziekteactiviteit	 als	 ziekteduur	 op	 het	 risico	 op	HVZ	 bij	 RA-patiënten	 te	 analyseren.	 Ziekteduur	
alleen	 lijkt	 geen	 significante	 onafhankelijke	 risicofactor	 te	 zijn	 in	 dat	 opzicht.	 Hoge	
ongecontroleerde	ziekteactiviteit	daarentegen	lijkt	onafhankelijk	het	risico	op	HVZ	significant	te	
verhogen.	 Verder	 werd	 gevonden	 dat	 lage	 ziekteactiviteit	 beschermend	 werkt	 tegen	 de	
ontwikkeling	van	HVZ,	zoals	behandeld	in	Hoofdstuk	7.	Opvallend	genoeg	bleek	uit	de	besproken	
resultaten	 dat	 remissie	 gemeten	met	 de	 DAS28	 (score	 voor	 ziekteactiviteit)	 geen	 significante	
toevoeging	lijkt	te	leveren	aan	dit	gunstige	effect.	Deze	bevindingen	ondersteunen	de	motivering	
voor	 direct	 strakke	 regulering	 of	 ‘tight	 control’	 van	 ziekteactiviteit	 bij	 patiënten	 met	 RA	 als	
preventieve	 strategie	 voor	 het	 voorkomen	 van	 HVZ	 in	 deze	 populatie.	 Daarnaast	 lijkt	 het	
cardiovasculair	risicoprofiel	van	patiënten	met	RA	aanzienlijk	te	verschillen	van	het	risicoprofiel	





Concluderend	 hebben	 patiënten	 met	 RA	 een	 verhoogd	 risico	 op	 HVZ	 waarbij	 systemische	
ontstekingsactiviteit	een	centrale	rol	lijkt	te	spelen;	zowel	als	een	onafhankelijke	risicofactor,	als	
door	effectmodulatie	van	andere	traditionele	risicofactoren.	Het	risicoprofiel	van	RA-patiënten	
lijkt	 daarmee	 te	 opvallend	 te	 verschillen	 van	 de	 algemene	 populatie.	 De	 beschikbare	
cardiovasculaire	 risicomodellen	 leveren	 suboptimale	 risicoschattingen	 bij	 RA-patiënten.	 Er	 is	
echter	geen	geschikt	alternatief	beschikbaar	op	dit	moment.	Daarom	is	het	gebruik	van	bestaande	
richtlijnen	en	aanbevelingen	op	het	gebied	van	cardiovasculair	risicomanagement	mogelijk	voor	
nu	 de	 beste	 oplossing,	 waarbij	 men	 bovengenoemde	 resultaten	 in	 het	 achterhoofd	 houdt	
wanneer	 deze	 toegepast	 worden	 op	 patiënten	 met	 RA.	 Naast	 aandacht	 voor	 traditionele	




















































































breedhoeklens,	 filters,	computerprogramma’s,	 tips	voor	het	zelf	 regelen	van	reizen	naar	verre	
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met	 reumatoïde	 artritis,	 in	 het	 bijzonder	 naar	 risicomodellen	 en	 de	 rol	 van	 systemische	
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